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The cornerstone of anti-infective therapy is attainment of the effective target concentration of the 
drug at the site of infection; achieving this goal requires integration of the pharmacokinetic and 
pharmacodynamics properties of the anti-infective drug. In this interplay, systemic and local 
quantitative analysis of the drug plays an integral part in providing information about the 
pharmacokinetic and pharmacodynamic properties of the anti-infective; this information is 
critical for drug development as well as evaluation of adequacy of established therapies. In this 
thesis, we will demonstrate the role of systemic and local quantitative analysis in the 
development of preventative strategies for HIV and also, the role of quantitative analysis in 
assessing adequacy of therapy in pediatric tuberculosis (TB). 
 
The projects in this thesis highlight the various points that are key for successful use of anti-
infective drugs. The first two projects, CHARM-01 and CHARM-02, focus on use of anti-
infectives for prophylaxis; specifically the development of tenofovir (TFV)-containing gels as 
locally applied (rectal) microbicides. Since these gels are locally-dosed, there are several factors 
that have to be considered such as the mucosal safety of the formulations, the ability of the 
formulations to cover all potentially HIV-exposed mucosa, and the ability to reach the optimal 
concentration of the active drug, TFV diphosphate (TDF-DP) to prevent HIV infection. 
 
In contrast, the PHATISA project looks at systemic (oral) dosing of anti-TB drugs in children for 
treatment. Children are a unique population in that optimal therapy has to account for the 
differences in absorption, distribution, metabolism and excretion of xenobiotic in the growing, 
ever-changing child. For instance, children have a less acidic gastric environment and their 
gastric motility is slow, which may affect the absorption of drugs. Children, mainly neonates and 
infants, have different water body composition as compared to older children and adults, which 
may affect the volume of distribution of drugs. The ontogeny of metabolic enzymes may affect 
the degree of metabolism that goes on at a specific age, and immaturity of the kidneys will affect 
the excretion of drugs. Unfortunately, most drug regimens used in children are extrapolated from 
adult dosing, which does not consider the abovementioned factors that are unique to children9. In 
the PHATISA study, we sought to evaluate whether a revised WHO-recommendation for TB 
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              Chapter 1. Introduction 
 
The cornerstone of anti-infective therapy is attainment of the effective target 
concentration of the drug at the site of infection; achieving this goal requires integration 
of the pharmacokinetic and pharmacodynamics properties of the anti-infective drug1.  In 
this interplay, systemic and local quantitative analysis of the drug plays an integral part 
in providing information about the pharmacokinetic and pharmacodynamic properties 
of the anti-infective; this information is critical for drug development as well as 
evaluation of adequacy of established therapies. In this thesis, we will demonstrate the 
role of systemic and local quantitative analysis in the development of preventative 
strategies for HIV and also, the role of quantitative analysis in assessing adequacy of 
therapy in pediatric tuberculosis (TB).  
 
The projects in this thesis highlight the various points that are key for successful use of 
anti-infective drugs. The first two projects, CHARM-01 and CHARM-02, focus on use of 
anti-infectives for prophylaxis; specifically the development of tenofovir (TFV)-
containing gels as locally applied (rectal) microbicides.  Since these gels are locally-
dosed, there are several factors that have to be considered such as the mucosal safety 
of the formulations, the ability of the formulations to cover all potentially HIV-exposed 
mucosa, and the ability to reach the optimal concentration of the active drug, TFV 




In contrast, the PHATISA project looks at systemic (oral) dosing of anti-TB drugs in 
children for treatment. Children are a unique population in that optimal therapy has to 
account for the differences in absorption, distribution, metabolism and excretion of 
xenobiotic in the growing, ever-changing child.  For instance, children have a less acidic 
gastric environment and their gastric motility is slow, which may affect the absorption of 
drugs.6 Children, mainly neonates and infants, have different water body composition as 
compared to older children and adults, which may affect the volume of distribution of 
drugs.  The ontogeny of metabolic enzymes may affect the degree of metabolism that 
goes on at a specific age, and immaturity of the kidneys will affect the excretion of 
drugs6-8. Unfortunately, most drug regimens used in children are extrapolated from 
adult dosing, which does not consider the abovementioned factors that are unique to 
children9. In the PHATISA study, we sought to evaluate whether a revised WHO-
recommendation for TB drugs is able to achieve the presumed optimal concentrations 
for treatment of TB in children.   
 
1.1. Microbicide Development for HIV Prevention 
             1.1. 1.  Rationale for microbicide development 
Though there has been a global decline in the incidence of HIV over the past decade, 
there were still more than 2 million new infections worldwide and close to 48,000 just in 
the United States in 201310,11. Both globally and regionally, the HIV epidemic 
disproportionately affects subgroups of the population, such as men having sex with 
men (MSM) 10-12Hence, methods augmenting current behavioral and biomedical 
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approaches are needed to control the HIV epidemic, and pre-exposure prophylaxis 
(PrEP) is one such key biomedical strategy.  
 
 HIV PrEP development has been ongoing in the past two decades. Data from animal 
models13-16 and experience of using antiretroviral drugs in prevention of mother-to-child 
transmission as well as use of anti-retroviral drugs (ARVs) for post-exposure prophylaxis 
gave initial impetus for the hypothesis that ARVs may be efficacious as PrEP. 
Subsequently, human clinical trials for PrEP have been carried out, most commonly, 
using TFV with or without emtricitabine.  In 2012, the Food and Drug Administration 
(FDA) approved the fixed dose combination of emtricitabine and TFV, marketed as 
TruvadaTM, for PrEP based on two randomized controlled trials (iPrEX study in MSM17 
and the Partner’s in Prevention study in discordant couples of heterosexual men and 
women18); these two studies showed HIV risk reduction by 44% and 75%, respectively19. 
  
1.1.2. Topical microbicides 
For PrEP development, attaining an anti-viral concentration that will prevent 
establishment of infection at the viral route of entry is critical. For example, for 
individuals at risk of HIV exposure via intravenous drug use, attainment of target 
concentration in blood is important. While, for those that are exposed to HIV via the 
sexual route, adequate anti-viral concentration at the site of the exposure to HIV, mainly 




With this in mind, there have been several clinical trials aimed at developing topical 
microbicides to be applied vaginally or rectally.  Topical microbicides have the 
advantage of minimizing systemic exposure while maximizing the local mucosal 
concentration, which makes them ideal for PrEP20-23. Early on, topical microbicide 
research focused on drugs presumed to act within the cervicovaginal lumen to prevent 
HIV from reaching its target CD4+ cells in cervicovaginal tissue. These products included 
Nonoxynol-9, other surfactants, and polyanions, which were all ineffective; some even 
increased the risk of HIV acquisition. Following these early disappointments, the field 
then shifted to formulations with antiretroviral drugs, which act directly on or within 
CD4+ cells, as topical microbicides24.  
 
The success of coitally dependent use of TFV 1% gel in reducing HIV in high risk women 
by 39% in the CAPRISA004 study provided a proof-of-concept for efficacy of topical 
microbicdes25. Given the disproportionate burden of HIV in men having sex with men for 
whom receptive anal intercourse is the primary route of HIV infection, rectal 
microbicide development has been a focus of several studies in recent years12,26-32. 
 
 
1.1.3. Key features of effective topical microbicide 
There are several key factors that determine the success of PrEP, which include 
adherence, drug concentration at exposure site, and susceptibility of the exposed 
mucosa to HIV infection, and the viral inoculum (i.e. viral load of the infectious 
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cervicovaginal fluid or semen of the infected partner)33. The critical role of adherence 
was delineated in the failure of the Fem-PrEP and the VOICES studies to demonstrate 
HIV prevention benefit34,35 , mainly resulting from low adherence in the study 
population. Even in the PrEP studies that showed efficacy (CAPRISA004, iPrEX, Partners 
in Prevention, and TDF2), those persons with higher adherence had fewer HIV 
acquisition events17,18,25,36.  The size of the HIV inoculum varies roughly with the viral 
load within the blood of the infected sexual partner and reduction of this viral load to 
undetectable levels reduces HIV transmission dramatically 37. Conversely, a high viral 
load is seen at the time of acute HIV infection and sexual exposure to an infected 
individual at this time could, presumably, overwhelm the effect of the microbicide38.  
 
Another key factor for success of PrEP is drug concentration at the exposed site. In 
development of PrEP, it is not the mere presence or absence of the antiviral drug at the 
mucosa, but the ability to achieve a sustained effective concentration for a period of 
time sufficient to “outlast” the viral exposure 20.  One of the many advantages of topical 
microbicides is the ability to achieve a high local concentration of the drug to maximize 
efficacy while achieving relatively little systemic exposure, thus, minimizing systemic 
toxicity.  For example, we know that tissue TFV concentration is 100 times higher after 
administration of a single vaginal gel dose than a single oral dose21-23.  
 
Integrity of the mucosa exposed to HIV also impacts the success of topical microbicides. 
We know that concurrent STIs that result in mucosal lesions and inflammation, such as 
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Herpes infection increase the risk of HIV acquisition. On the other hand, microbicide 
development also has to take into account that some microbicide formulations may 
increase the risk of HIV infection by damaging the mucosa. We know from prior 
lubricant and enema studies that formulations with high osmolality result in mucosal 
damage 39,40.  
 
One of the first trials of a rectal microbicide was MTN-006, which evaluated the TFV1% 
vaginal gel formulation (VF) for use as rectal microbicide41. The study showed that the 
high osmolality of the formulation resulted in unacceptably frequent gastrointestinal 
adverse events, albeit minor ones, which may compromise acceptability and the 
widespread use of the formulation. Following the results of MTN-006, a reduced 
glycerin formulation (RGVF) was designed and tested in MTN-00742. The result showed 
that the RGVF had less adverse events when compared to the VF formulation.  A third 
formulation designed specifically for rectal use (RF) was evaluated in CHARM 01 and 
CHARM 02, the focus of this thesis.  
 
1.1.4. CHARM-01 and CHARM-02 studies 
The CHARM-01 and CHARM-02 studies address several key determinants of candidate 
rectal microbicide success as PrEP:  mucosal safety, local and systemic concentration, 
colonic distribution, and effect of study gels on colonic permeability. The CHARM-02 
study compares the safety, systemic exposure, distribution in the colonic lumen and 
colonic permeability effects of a single dose of each of three candidate rectal 
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microbicide gels of 1% TFV with varying osmolalities: the rectal formulation (RF), the 
reduced glycerin formulation (RGVF), and the vaginal formulation (VF). On the other 
hand, the CHARM 01 compared the abovementioned candidate microbicide gels in 
multiple compartments (plasma, colonic mucosa, mucosal mononuclear cells, PBMCs, 
rectal and vaginal fluid) after 7 consecutive daily doses of the RF and RGFVF and a single 
dose of VF. 
 
The result of both studies demonstrated that all three products were safe as no severe 
adverse events (AE) were reported; however, the hyperosmolal product, VF, had more 
minor AE’s associated with it, mostly gastro-intestinal complaints.  The VF was also 
associated with increased permeability of the colon to the drug surrogate as measured 
by concentration of the drug surrogate in the blood and urine. Despite the two-fold 
difference in osmolality, the RF and RGVF did not drastically differ in their achieved 
concentration in the various compartments, and both have good distribution in the 
colonic mucosa.  
 
1.2. Assessment of Adequacy of TB drugs in Children 
1.2.1. Burden of Pediatric Tuberculosis 
One third of the world’s population is estimated to be infected with tuberculosis.  In 
2013, about 9 million new cases of TB and 1.5 million deaths were estimated, with the 
majority of the burden concentrated in South-East Asia, the Western Pacific, and the 
African regions43. Given their immature immune system, children bear the greatest 
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burden of morbidity and mortality. In 2013, it is estimated that about 550,000 new 
cases and 80,000 deaths occurred in children less than 15 years of age.  This estimate is 
likely a gross underestimation of pediatric TB burden, as it does not include HIV-TB co-
infected children. In addition, unlike in adults, diagnosis of tuberculosis in children is 
quite challenging. Unlike adults, children have non-specific symptoms, and also have 
pauci-bacillary disease. The most widely used diagnostic tool, sputum smear, is only 
positive in 5-10%, and the gold standard, sputum culture, is only positive in 40% of 
children with TB.44,45  
Another distinguishing characteristic of pediatric tuberculosis is that children are more 
prone to severe forms of tuberculosis due to their immature immune system.  In 
addition, since children have pauci-bacillary disease and are unlikely to transmit TB to 
others, most of the public health efforts have concentrated on adult TB, ignoring the 
pediatric disease.  
 
1.2.2. Tuberculosis therapy in adults  
Our current first-line tuberculosis (TB) therapy is composed of four-drug therapy: 
Isoniazid (INH), rifampin (RIF), pyrazinamide (PZA) and addition of ethambutol (EMB) (in 
areas with high INH resistance and for severe cases) for two months, followed by four 
months of INH and RIF.  These four drugs were instituted into TB therapy several 
decades ago:  INH in 1952, RIF in 1966, PZA in 1952, and EMB in 1961.46 The fact that 
these drugs remain a first-line regimen is telling of the stagnation in the realm of TB 
drug development. In fact, there is only one new class of TB drug approved since the last 
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TB drug approval in 197147, bedaquiline, which was approved in 201248 . Fortunately, 
there are a few new drugs in the pipeline, which may be available in the next few years. 
 
1.2.3. TB therapy in Children 
 There is a paucity of data in regards to optimal TB treatment in children. Most target 
concentrations for TB therapy in children are developed by extrapolation from adult 
data. This method is fraught with inaccuracies, as it does not take into account the 
differences between adults and pediatrics; as mentioned earlier, in addition to the 
obvious size differences, there are several differences including enzymatic ontogeny 
maturation, differences in volume of distribution and percent water in the body and 
maturation of organ system involved in clearance of these drugs.  
 
In 2009, McIlleron, et al., published a study looking at the WHO-recommended dosages 
for isoniazid in a pediatric population. They showed that 70% of the children that 
received the adult dose were actually underdosed49. Based on this information and 
meta-analysis of the few existing pediatric studies, the WHO released a rapid advice to 
change the recommended dosages, in some instances, doubling the previously 
recommended dose.  The report emphasized the paucity of data and critical need for 
PK/PD studies in children50. 
 
1.2.4. The PHATISA study 
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We conducted a prospective observational study in the province of Kwa Zulu Natal, 
South Africa – a region with one of the highest prevalence’s of TB – to look at the 
implementation of the new drug doses, and whether these recommended dosages did 
actually achieve the supposed therapeutic target concentrations.  
 
We recruited children under10 years of age that presented for care at a tertiary health 
care center, and initiated on first-line anti-TB regimen. Our study included children with 
HIV/TB co-infection. 
The study indicates that even with the increased dosage recommendation, many 
children did not achieve the presumed target concentrations for the four first-line TB 
drugs; the result was more striking for under-dosing of rifampin. Overall, the study 
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Objective: CHARM-02 is a cross-over, double-blind, randomized trial to compare the safety and 
pharmacokinetics of three rectally applied tenofovir 1% gel candidate rectal microbicides of 
varying osmolalities: vaginal formulation, VF (3111 mOsmol/kg); the reduced glycerin vaginal 
formulation, RGVF (836 mOsmol/kg); and an iso-osmolal rectal-specific formulation, RF (479 
mOsmol/kg). 
Materials and Methods: Participants (n=9) received a single, 4ml, radiolabeled dose of each gel 
twice, once with and once without simulated unprotected receptive anal intercourse (RAI). 
Safety, plasma tenofovir pharmacokinetics, colonic small molecule permeability, and SPECT/CT 
imaging of lower gastrointestinal distribution of drug and virus surrogate were assessed. 
Results: There were no Grade 3 or 4 adverse events reported for any of the products.  Overall, 
there were more Grade 2 adverse events in the VF group compared to RF (p=0.006) and RGVF 
(p=0.048). In the absence of simulated unprotected RAI, VF had up to 3.8-fold greater systemic 
tenofovir exposure, 26-234-fold higher colonic permeability of the drug surrogate, and 1.5-2-
fold greater proximal migration in the colonic lumen, when compared to RF and RGVF. Similar 
trends were observed with simulated unprotected RAI, but most did not reach statistical 
significance. SPECT analysis showed 86% (standard deviation 19%) of the drug surrogate co-
localized with the virus surrogate in the colonic lumen. There were no significant differences 
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between RGVF and RF formulation, with the exception of higher plasma tenofovir 
concentration of RGVF in absence of simulated unprotected RAI. 
Conclusion: VF had the most adverse events, highest plasma tenofovir concentrations, greater 
mucosal permeability of the drug surrogate, and most proximal colonic luminal migration 
compared to RF and RGVF formulations. There were no major differences between RF and 
RGVF formulations. Simultaneous assessment of toxicity, systemic and luminal 
pharmacokinetics, and co-localization of drug and viral surrogates, substantially informs rectal 





Even though the incidence of HIV is declining in many regions globally, men who have sex with 
men (MSM) continue to be affected disproportionately and increasingly. Global MSM incidence 
estimates are difficult due to poor surveillance in this group; however, the limited available 
data shows that MSM carry a high burden of HIV in high-income countries as well as in low and 
middle-income countries.12,26-32,51,52 In the United States, despite an overall decline in incidence 
of HIV, the incidence of HIV in men having sex with men (MSM) has been increasing 
significantly, with data from 2010 showing a 12% rise in incidence of HIV.53 Hence, prevention 
of HIV in this vulnerable group, including biomedical interventions like rectal microbicides (RM), 
is vital. 
Key features of successful RM development include safety, efficacy and acceptability of the 
product by the target population. RM have the advantageous feature of directly targeting the 
colonic mucosa that is at risk of HIV infection with high antiretroviral (ARV) drug concentrations 
while simultaneously limiting systemic exposure and potential toxicity.54 High local 
concentrations may also enable periodic dosing by achieving local tissue concentrations above 
protective target concentrations more rapidly than can be achieved by oral dosing. However, 
locally high concentrations need to be developed carefully to rule out local toxicity.  
Encouraged by the success of oral pre-exposure prophylaxis (PrEP) with tenofovir (TFV)-
containing regimens 17,18,36,55, TFV, a potent nucleotide reverse transcriptase inhibitor (NRTI) 
with a long intracellular active drug half-life, is being investigated as a RM. RMP-02/MTN-006 
evaluated rectal application of the vaginal formulation (VF) TFV 1% gel, the formulation used in 
CAPRISA 004 and VOICE studies for vaginal application25,41,56, and found a rate of minor adverse 
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events too frequent to recommend further development as a RM. The gastrointestinal related 
adverse events were attributed, in part, to the very high osmolality (3111 mOsmol/kg) of the 
formulation. Subsequently, a TFV 1% reduced glycerin formulation (RGVF) with far lower 
osmolality (836 mOsmol/kg) was studied in MTN-007 showing that RGVF was safe and well 
tolerated 42. Based on these favorable tolerability results, a phase II trial of the RGVF gel is now 
underway (MTN-017). A third TFV 1% gel, formulated specifically for rectal use (rectal 
formulation, RF) has been developed to achieve even lower, near physiologic, osmolality (479 
mOsmol/kg) and pH value closer that of the rectum (pH close to 7)57.  The RF vehicle was 
selected from among four candidate RM vehicles based on PK/PD, toxicity and acceptability58. 
The current study, Combination HIV Antiretroviral Rectal Microbicide (CHARM) 02 (CHARM-02), 
is a double-blinded, randomized, pharmacokinetic and safety study of three rectally applied TFV 
1% gel candidate rectal microbicide formulations; the VF, RGVF, and, RF are distinguished 
primarily by their far different osmolalities. The goals of the study were to evaluate the safety, 
systemic TFV pharmacokinetics (PK), colonic luminal distribution and clearance of the three 
gels, and their impact on mucosal permeability. In addition, we assessed the degree of overlap 
in the colonic luminal distribution for each of the gels with a surrogate for HIV-infected 
ejaculate. CHARM-02 was designed as a complement to, and performed in parallel with, 
CHARM-01 whose objectives included multi-compartmental PK, a detailed mucosal safety 
assessment, and an evaluation of the HIV protective effect using an ex vivo colorectal HIV-1 




Materials and Methods 
Study design and participants 
The Johns Hopkins Medicine Institutional Review Board approved this single-center, 
randomized, double-blinded, crossover study of three TFV 1% gel formulations. All research 
participants completed a written informed consent prior to screening. Eligible participants were 
healthy, male, HIV seronegative adults with history of consensual receptive anal intercourse 
(RAI) at least once within the six months prior to screening. All participants received each study 
gel twice, once with and once without simulated unprotected RAI. There was a minimum of 11 
days washout period between each gel administration (Supplemental Appendix 1: Protocol). 
The primary safety endpoint was Grade 2 or higher clinical or laboratory adverse events as 
defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric adverse 
events, version 1.0, December 2004 as well as addendum 3 (Rectal Grading Table for Use in 
microbicide Studies)60.  Primary pharmacokinetic endpoints include plasma TFV concentration, 
luminal distribution of the drug and viral surrogates and impact on mucosal permeability of the 
three gel formulations. 
Dose preparation and administration 
The three rectally applied TFV 1% formulations in this study are a vaginal formulation (VF), a 
reduced-glycerin vaginal formulation (RGVF) and a rectal-specific formulation (RF). Study 
investigators administered all doses in the research clinic. Each dose of the study gels was 
111In-diethylene-triamine-pentaacetic acid (111In-DTPA, 
Cardinal Health, Halethorpe, MD) with 4mL of the study gel as the radiolabeled study drug 
surrogate.  In addition, for the visits with simulated RAI, 500 Ci 99mTc-sulfur colloid (99mTc-SC) 
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was mixed with 2.5mL of autologous seminal plasma, and administered 60 minutes after gel 
product dosing as the HIV surrogate (based on similar 100 nm sulfur colloid particle size in a 
colloidal suspension). The seminal plasma was collected prior to the study dosing visits in one 
or several outpatient visits to the research clinic until adequate semen volume was acquired.  
 In order to quantitatively describe the distribution of the formulation following addition of 
ejaculate and the potential for mixing due to the coital forces, simulated unprotected RAI with 
autologous semen was carried out. All participants received a bowel preparation using a 
Normosol-R (Abbott Laboratories) enema to remove bowel contents from the distal colon and 
to more closely match realistic clinical conditions in which these rectal products will be used. 
Normosol, a pH and salt-balanced electrolyte solution for licensed intravenous administration 
and fluid replacement, was chosen in order to reduce confounding toxicity to the colonic 
mucosa.  The research participant then inserts a single-use artificial phallus with catheter in 
urethral position into rectum and cycles the devices in and out of the rectum to its full extent 
once each second for 5 minutes. With the phallus remaining in situ, the autologous semen 
sample, radiolabeled with 99m-Tc-sulfur colloid, is injected by the study team member through 
catheter within the device. The subject then resumes simulated intercourse with 10 more 
in/out cycles of the device and then removes the device. This procedure has been used 
successfully in previous studies.61 
Safety and Acceptability:  Safety of the three products was assessed during the entire study 
period; participants were asked about any adverse event during each study visit, which were 
followed by a directed physical examination and safety laboratory examination. They were also 
instructed to contact the investigators should any adverse event occur while they were at 
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home.   Acceptability of each study product was evaluated through administration of a brief 
questionnaire after each dose.   
Drug concentration analysis 
Blood samples (4mL) were drawn in K2EDTA vacutainer tubes (BD, Franklin Lakes, NJ) at pre-
dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.33, 2.66, 3, 3.5, 4, 8, 12 and 24 h post dose; plasma 
was separated from the tubes after centrifugation at 1000x g for 10 minutes at 4 oC. Aliquots 
were set aside for gamma counting (permeability) and aliquots were stored at -80 0C for 
batched TFV analysis. TFV concentrations were determined by a previously validated ultra 
performance-liquid chromatographic-tandem mass spectrometric (UPLC-MS/MS) method at 
The Johns Hopkins University Clinical Pharmacology Analytical Laboratory (CPAL)21,62.  The assay 
had a lower limit of quantification of 0.31 ng/mL.  Peak concentration (Cmax), times to peak 
concentration (Tmax), and area under the concentration-time curve for 24 hours (AUC0-24) were 
calculated using WinNonlin (Pharsight, 6.3, Cary, NC). 
SPECT/CT Imaging distribution 
Two hours and 24 hours after each gel administration, participants underwent single photon 
emission computed tomography with transmission computed tomography (SPECT/CT) to 
determine the luminal distribution and clearance of each study gel radiolabel (111In-DTPA) and 
whole semen radiolabel (99Tc-Sulfur colloid). Participants were imaged using a dual-head VG 
SPECT series system (GE Medical Systems, Waukesha, WI) equipped with a CT unit (Hawkeye) 
as previously described.61,63 CT images were reconstructed with a filtered back projection 
algorithm onto a 256 × 256-matrix size. After SPECT acquisition, images were reconstructed 
using the OSEM algorithm and fused with CT images, into a 128 x 128 x 128 matrix size with 
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each voxel representing 3.45 mm3, using the General Electric eNTEGRA workstation, software 
version 1.04 (GE Medical Systems, Waukesha, WI) 64. 
Curve-fitting and concentration-by-distance calculations were performed using R version 3.1.0 
(The R Foundation for Statistical Computing, Vienna, Austria) per previously described 
algorithms63,65. Briefly, a flexible principal curve algorithm was used to construct a three-
dimensional curve based on the colon images. After the centerline was constructed, a 
concentration-by-distance curve was estimated along the centerline using the orthogonal 
projections. For standardizing distances within and among research participants, the readily 
identifiable coccygeal plane in the CT (axial view) was used as the origin (z=0 value) of the 
centerline as previously described66. The distance along the centerline between the origin of 
the radiolabel signal and the coccygeal plane was recorded as Dmin (minimum distance 
associated with the closest, most distal, point where radiolabel was detected within the lumen 
of the colon) with negative values indicating radiolabel origin below the coccyx and positive 
values indicating centerline origin above the coccyx in the cranio-caudal axis. Previously defined 
imaging pharmacokinetic-distance parameters – Dmax (distance associated with the most 
proximal radiolabel signal within the colon), DCmax (distance associated with maximum 
concentration), and Dave (mean residence distance) – were calculated for further analysis
66.  
Mucosal permeability. Blood samples were collected at the same 17-time points as for plasma 
TFV PK. Urine samples were collected in three intervals: 0-2hrs, 2-4hrs, and 4-8 hours post 
dose. Gamma emissions in 1 ml aliquots were measured on a gamma counter (Wizard2 
automatic gamma counter model 2480, PerkinElmer, Waltham, MA) within a 110–150-keV 
energy window, and data corrected for decay relative to the time of dosing.  Urine gamma 
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emission results were also volume-corrected. Radioactivity was expressed as a fraction of the 
dose administered in order to normalize readouts among subjects and products. Plasma 111In-
DTPA results were analyzed by calculating the Cmax, Tmax, and AUC0-24. For urine, maximum 
observed urine excretion rate (Max rate), area under urinary excretion curve (AURC) and 
percent of dose recovered in urine (%recovered) were calculated. Both plasma and urine 
analysis were carried out using WinNonlin (Pharsight, 6.3, Cary NC).  
Dual Isotope 111In and 99mTC Image Analysis 
We determined the fraction of the HIV surrogate (99mTc-SC) co-located with microbicide 
surrogate (111In-DTPA) to delineate the adequacy of the study product distribution relative to 
the HIV surrogate distribution. Cross-talk correction was performed using previously described 
methods67,68. Using R (version 3.1.2), all voxels with high 99mTc were selected and defined as 
“voxels at risk” (VAR).  In order to remove scattered voxels far from the region of interest, only 
200 or more contiguous voxels among the VAR, named contiguous VAR (cVAR), were 
considered. 
For this analysis, we used the 99.99% quantile of the intensities of a pure background signal 
(abdominal location inconsistent with colon distribution) for 99mTc and 111In, respectively, as a 
scan-specific threshold. Within the cVAR in each scan, two quantities 𝑝𝑣 and 𝑝𝑖 were calculated: 
𝑝𝑣 is the proportion of voxels with both high 
99mTc and high 111In among all the cVAR; 𝑝𝑖 is 
similar to 𝑝𝑣, but indicates the gamma signal intensity based proportion which is the sum of 
intensities of 99mTc of voxels with high 99mTc and high 111In among the total sum of intensities of 
99mTc in cVAR.  Both quantities indicate the proportion of 99mTc covered by 111In among all the 
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99mTc within cVAR, the only difference is that 𝑝𝑣 is voxel-based while 𝑝𝑖 is an intensity (mass)-
weighted version of 𝑝𝑣.  
Data analysis and sample size: A sample size of 9 research participants was calculated to detect 
a 0.7 difference in proportion of adverse events and a standardized mean difference of 0.93 in 
the pharmacokinetic-distance or permeability outcomes between any of the study gel 
formulations in a paired analysis with 80% power using 2-sided, 5% alpha error.   Data were 
analyzed using the statistical package STATA/IC 13.1 software (StataCorp LP, College Station, 
TX). Statistical significance was defined as a p-value < 0.05.The number and frequency of Grade 
2 or higher AEs were tabulated for each of the 3 study formulations after the final dosing visit. 
The proportion of events was compared between each pair of formulation using McNemar’s 
test. Friedman test was used to assess differences in frequency of AEs among study products, 
and  based on the result,  a Wilcoxon Rank Sum test was utilized for pairwise analysis.  For 
comparison of plasma TFV PK, pharmacokinetic-distance, and mucosal permeability outcomes, 
Wilcoxon rank sum paired analysis was used. In addition, to delineate linear correlation 
between plasma TFV concentrations and mucosal permeability, a Pearson’s correlation 





Seventeen men provided written informed consent and were screened (Figure 1). Of these, 9 
fulfilled the inclusion and exclusion criteria and were enrolled.  Mean age of the research 
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participants was 41.8 years (standard deviation [SD] 9.3). Three were European American and 6 
were African American by their own report. Data from all nine participants were included for 
adverse event analysis (safety cohort). Data from 8 were included in the other analyses (PK 
cohort). One research participant was excluded from the PK cohort due to laboratory evidence 
that he was surreptitiously taking tenofovir/emtricitabine during the study period. 
Adverse Events 
Overall, there were 54 adverse events (AE) and there were no Grade 3 or 4 AEs. AEs were more 
common when participants were receiving VF (6/9) as compared to RF (1/9) or RGVF (3/9)(table 
1).  Pairwise comparison revealed a statistically significant higher number of overall Grade 2 AEs 
in the VF group as compared to RF (13 vs. 1, p=0.006) and RGVF (13 vs. 5, p=0.048).  
Twenty-three of the AEs (41.8%) were deemed related to the study gels, and all but one of 
these events were Grade 1.  All of the 23 AEs were gastro-intestinal in nature, including 
abdominal cramps (34.8%), diarrhea (26%), bloating/flatulence (21.7), urgency (8.7%), 
proctalgia (4.4%) and rectal bleeding (4.4%). There were numerically higher number of AEs in 
VF as compared to RGVF and VF, which did not reach statistical significance in pairwise analysis 
(Figure 2 and Table 1). 
 
Plasma pharmacokinetics of Tenofovir 
In the absence of simulated unprotected RAI, the median Cmax of TFV for the VF formulation 
was 6.4-fold higher than for the RF (p=0.009)(Table 2). VF also had a 4-fold higher median Cmax 
than RGVF, but this did not reach statistical significance (p=0.06).  Median Cmax for RGVF was 
also 1.6-times higher than RF (p=0.005).  With simulated unprotected RAI, the trend of higher 
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median Cmax for VF was also observed, but only the difference in Cmax for VF and RGVF was 
statistically significant (36.5 ng/mL vs. 6.87ng/mL, respectively, p=0.03)(Figure 3 and Table 2).  
In addition, there was a statistically significant shorter Tmax observed for VF when compared to 
the RF formulation (1.18 hrs vs. 2.85 hrs, p=0.005 without simulated RAI, 1.26 vs. 1.65hrs, 
p=0.016 with simulated unprotected RAI).  
Similar to the trend noted for Cmax, there was an overall trend of higher AUC0-24 for the VF 
formulation, both in the absence and presence of simulated unprotected RAI; however, only 
the comparison of VF and RGVF yielded a statistically significant difference, with VF having a 
3.8-fold higher AUC0-24 than RGVF (p=0.027).  
Imaging Distribution 
Of the forty-eight 2-hour post dose SPECT/CT scans that were scheduled, all were completed. 
Three (2 RF, 1VF) did not show any microbicide or HIV surrogate signal due to loss of isotope as 
a result of a bowel movement prior to imaging.  The 24-hours post dose scans were 
discontinued after the first 5 scans in which there was no signal detected due to a combination 
of radioactive decay and bowel movements.  
For the analysis of the drug surrogate (111In-DTPA) in the absence of simulated RAI, there was a 
statistically significant difference in Dmax and Dave for VF when compared to RF and RGVF; Dmax 
for VF was 1.5-times and 2-times higher than RF and RGVF, respectively (p=0.04 and 
0.002)(Table 3). Similarly, Dave for VF was 2.9- and 2.1-times higher than RF and RGVF, 
respectively (p=0.015 and 0.02). In contrast, there was no statistically significant difference in 
DCmax among the three products, although VF medians were higher than the other 
formulations. There was also no difference in Dmin among the products.  In the presence of 
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simulated RAI, VF had numerically higher medians of Dmax, DCmax, Dmin, and Dave when compared 
to RF and RGVF, but none of these reached statistical significance.  
When comparing the distribution of the drug and the HIV surrogate, there was no statistically 
significant difference in Dmax and DCmax. There was a trend of higher Dave for the drug surrogate 
in RF and RGVF, but it did not reach statistical significance (p=0.06 and 0.07, respectively)(Table 
4).  The drug surrogate was closer to the anus when compared to the HIV surrogate for the RF 
and RGVF (p=0.004 and 0.002, respectively). Sample SPECT images and distance-concentration 
plots are depicted in Figure 4 a-c.  
Adjusted for the mass of the HIV surrogate in each voxel, 86% (SD 0.19) of the HIV surrogate 
was co-located with the drug surrogate; without the mass adjustment (simply comparing 
coincident radiolabel voxel-by-voxel, regardless of the amount in each voxel), the mean 
percentage coverage goes down to 36.2% (SD 0.13). There was no statistically significant 
difference in percent coverage of the HIV surrogate among the three gel formulations using 
either co-localization method. 
 
Mucosal Permeability 
Plasma 111In-DTPA PK. In the absence of simulated RAI, dose-adjusted median Cmax for VF was 
34-fold and 7-fold higher than RF and RGVF, respectively (p=0.006 and 0.02)(Table 5a). A larger 
difference was noted with AUC, with VF 234-fold, and 26-fold higher when compared to RF and 
RGVF, respectively (p=0.005 and 0.02).  Median Cmax and AUC, larger for RGVF compared to RF, 
nearly achieved statistical significance (p=0.06 and 0.08, respectively).  
29 
 
With simulated RAI, a similar pattern was noted with the dose-adjusted median Cmax for VF 
being 7-fold and 8-fold higher than RF and RGVF, respectively (p=0.02 and 0.03). The median 
AUC for VF was 63-times and 32-fold higher than RF and RGVF (p=0.02 for both). There was no 
difference in AUC between RF and RGVF. There was also no statistically significant difference in 
regards to permeability Tmax among the three products, with or without simulated RAI.  
Comparing the permeability PK parameters in the presence and absence of simulated RAI for 
each product, there was a pattern of numerically higher median Cmax and AUC for all three 
products with coital simulation; however, only median Cmax for RF, comparing with and without 
simulated RAI, reached statistical significance, with a 9-fold increase in Cmax with coital 
simulation (p=0.03). 
We also found a significant linear correlation(r=0.83, p<0.001) between plasma TFV 
concentration and plasma 111In-DTPA(Figure 5a). 
Urine 111In-DTPA PK. In the absence of simulated RAI, maximum observed excretion rate for VF 
was 6.6-times and 3.2-times higher than RF and RGVF (p=0.016 and 0.046)(Table 5b).  The area 
under the urinary excretion rate curve (AURC) for VF was 5-times and 2.7-times higher than RF 
and RGVF, respectively (p=0.01 and 0.03). The percent of 111In-DTPA recovered in urine for VF 
was also significantly higher for VF as compared to the RF and RGVF, 1.75-times and 4.7-times 
higher, respectively (p=0.046 and 0.009).  
With simulated RAI, similar results were seen with 2.8-times and 7.25-times higher maximum 
observed excretion rate for VF as compared to RF and RGVF, respectively (p=0.036 and 0.021). 
The AURC for VF was 2.8-times, and 5.8-times higher than RF and RGVF, respectively (p=0.027 
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and 0.016). Also, the percent of drug surrogate recovered for VF in urine was higher than RF 
and RGVF by 1.75-fold and 4.7-fold, respectively (p=0.046 and 0.009). 
There was no difference noted between the maximum observed excretion rate, area under the 
urinary excretion rate curve or percent recovery of the In-DTPA from the urine when comparing 
the RF and RGVF.  Among and between products, there was no statistical difference between 
median maximum excretion rate, AURC and % recovered from urine when comparing values in 
the presence and absence of simulated RAI. There was a significant correlation between plasma 




The CHARM-02 study showed that a single rectal dose of the three TFV gel formulations under 
study, was safe as there was no Grade 3 or 4 toxicity reported. However, minor adverse events 
were more common with VF as compared to the RGVF and RF. Similar results were observed in 
the companion study, CHARM-01, with VF accounting for 48% of reported adverse events in the 
entire study, despite only one VF dose being administered, compared to 7 consecutive doses of 
each for RF and RGVF59.   
Systemic TFV exposure was greater following VF dosing compared to the other formulations 
without simulated RAI, but depended on which PK parameter was compared. With the VF 
formulation, TFV Cmax was 6-fold higher and twice as rapid when compared to RF in the absence 
of simulated RAI. TFV AUC was 3.8-fold higher with VF than RGVF. RGVF also achieved higher 
peak concentrations than RF. This general trend of greater systemic exposure correlating with 
increased osmolality is seen to an even greater extent with permeability for DTPA (discussed 
below). With simulated unprotected RAI, these patterns generally persisted, but lost statistical 
significance. As simulated unprotected RAI generally increased permeability of TFV and DTPA, 
this may have had a leveling effect on the differences seen without RAI. Also, plasma TFV 
correlated with the 111In-DTPA permeability estimates, though TFV permeability was of much 
smaller magnitude compared to DTPA. The difference could be partly attributed to the 
relatively poor bioavailability of the charged TFV molecule relative to DTPA.  The high 
correlations for DTPA permeability measurements and plasma TFV concentration suggests   
Indium-DTPA can serve as a reasonable model for permeability measurement for TFV 
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Imaging of the drug surrogate in the absence of simulated unprotected RAI revealed 
significantly higher colonic mucosal distribution (Dmax and Dave) of VF when compared to RF and 
RGVF. This may best be explained by the far greater osmolality of VF which draws significantly 
more fluid into the colonic lumen, thus, increasing the spread of the radiolabel after dosing 
relative to the lower osmolality RGVF and RF formulations. It is noteworthy that RF and RGVF 
were not different in their luminal distribution in the colon. 
Our weighted dual isotope analysis showed that 86% of the viral surrogate was co-located or 
“covered” by the drug surrogate and was not different among the formulations. We believe this 
to be a critically important variable since the goal of rectal microbicide development is to 
develop a formulation that can outdistance and outlast HIV. This dual isotope analysis reflects a 
high degree of concordant drug-HIV distribution within the lumen, but it doesn’t assess 
mucosal coverage, per se, given the resolution of the radiographic method. Animal studies 
using fluorescent labeling and histologic imaging enable a more direct assessment of mucosal 
coverage69. These studies indicate optimal mucosal coverage with iso-osmolar and slightly 
hypotonic products. Finally, none of these methods address diffusion of drug or HIV into the 
mucosal tissue over time.  
The striking difference in mucosal permeability among the study gels was evidenced by the 
plasma and urine concentration of the drug surrogate (111In-DTPA). Plasma Cmax and AUC of the 
drug surrogate for VF were greater than 30-fold and 200-fold, respectively, when compared to 
the RF, in the absence of simulated RAI. Statistically significant, but smaller magnitude 
differences, were seen for RGVF compared to VF. RGVF trended toward values greater than RF. 
Similar patterns were seen with simulated RAI.  These DTPA permeability differences are 
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consistent with the osmolality differences among the study products. Generally, for both TFV 
and DTPA colonic mucosal permeability, the greater the osmolality, the greater the systemic 
exposure: VF > RGVF > RF. This suggests that the predominant effect of the hyperosmolar gels 
was increased colonic mucosal permeability, which more than counterbalanced the competing 
physiologic effect of increased fluid from colon tissue into the colonic lumen with higher 
osmolarity products.  Besides osmolality, there may be other differences between products 
(e.g., pH and viscosity) that contributed to the results, although given size of the compartment 
and the rectum’s ability to buffer pH, such contributions are presumed to be minimal.70 It is 
notable, that there are not more consistent differences between the RGVF and RF given the 
nearly 2-fold difference in osmolality. This may be due, in part, to mitigation of some 
anticipated mucosal integrity-related differences by offsetting hyperosmolarity-related fluid 
fluxes into the colonic lumen. 
Since we did not assess histologic damage or HIV infectivity, we cannot tell if these permeability 
differences increase HIV infection risk. Our previously published works with hyperosmolar 
sexual lubricants and hyperosmolar enemas are consistent with our CHARM-02 permeability 
observations40,71. Unlike CHARM-02, both of those earlier studies included colon biopsies and 
both demonstrated greater loss of the colonic single columnar epithelial layer associated with 
very high osmolality products -  2,100 mOsmol/kg Fleet enema40 and 3,429 mOsmol/kg 
commercial sexual lubricant 71 – when compared to iso-osmolar controls.  
Hence, a significant limitation of the current study is that no biopsies were obtained; so, 
histologic toxicity, tissue PK, and susceptibility to ex-vivo HIV infection were not assessed. Other 
than inferring potential mucosal alteration based on the TFV and drug surrogate concentrations 
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in plasma and urine, there was no histological examination performed to evaluate structural 
changes in the mucosa. The companion study, CHARM-01, included intensive safety analyses 
which included histology, microbiology, and susceptibility to ex-vivo HIV infection. We chose 
not to perform intraluminal manipulations to capture biopsies given our primary goal of 
assessing colonic luminal drug and HIV surrogate distribution, both of which we wanted to 
assess unperturbed by endoscopic instrumentation.  
VF is no longer under development as a rectal microbicide given the adverse effect profile and 
safety concerns with rectal use, some of which are reinforced in this study. The incorporation of 
simulated RAI in CHARM-02 proves critical in the comparison of the novel RF formulation being 
compared to RGVF for the first time in CHARM-01 and CHARM-02. CHARM-02 demonstrated 
that while RGVF demonstrated greater plasma TFV concentrations and a trend toward greater 
mucosal permeability compared to RF, these differences disappeared with simulated RAI. 
Further, RGVF and RF had similar, excellent co-distribution of drug and HIV surrogates. Of note, 
there were slightly more frequent minor adverse events reported in RGVF group compared to 
RF, but these differences were not statistically significant. On the basis of these observations 
and the CHARM-01 findings, we do not find a compelling advantage of RF over RGVF. There are 
two ongoing clinical studies of the RGVF formulation, PROJECT GEL and MTN-017. The results of 
these studies, especially MTN-017, which is an international, multi-center phase II trial, will 






Table 1. Proportion and frequency of overall Grade 2 adverse events and frequency of  AEs 
deemed related to study product 
 
     p-values  
  
RF                   RGF                        VF 
RF vs. 
RGVF 
RF vs. VF RGVF vs. 
VF 
Participants (n,%) 
with Grade 2 
AE(n=9) 
1(11.1%) 3(33.3%) 6(66.7%) 0.63* 0.063* 0.38* 
Number of Grade 2 
AEs(n, %)(n=18) 
1(5.3%) 5(26.3) 12(68.4%) 0.5** 0.006** 0.048** 
Number of Grade 1 
and 2 AEs deemed 
study-product 
related, (n, %)(n=23) 
4(17.4%) 6(26.1%) 13(56.5%) 0.58** 0.09** 0.19** 
*p-values derived from pairwise comparison of formulations using McNemar’s test 
**p-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum 
test; these were performed after a Friedman test showed differences in frequency of 
































Cmax(ng/ml)*       









0.035 0.009 0.06 






0.53 0.093 0.03 
Tmax(hr)*       









0.07 0.005 0.67 






0.19 0.016 0.1 
AUC0-24* 
(ng.hr/ml) 
      









0.67 0.09 0.14 






0.46 0.09 0.027 
 
SURAI: Simulated unprotected receptive anal intercourse; *Comparison of SURAI vs. no SURAI 
for each PK-parameter yielded p-value>0.05. 
P-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum test; 







Table 3.  Drug surrogate (111In-DTPA) imaging pharmacokinetic-distance parameters in 
centimeter by product at 2 hours after dosing; median (25th percentile, 75th percentile) 




VF vs. RF 
P-value 
VF vs. RGVF 










0.16 0.037 0.0023 









0.64 0.28 0.42 










0.73 0.25 0.67 







0.64 0.95 0.56 










0.64 0.25 0.46 









0.64 0.28 0.56 










1 0.015 0.021 






0.92 0.42 0.30 
 
Note: The coccyx is the reference point for all the distance variables above. 
SURAI: Simulated unprotected receptive anal intercourse; Dmax: furthest point where 
radiosignal was detected; DCmax: distance at maximum concentration; Dave: mean residence 
distance; Dmin: distance associated with the most distal signal; CDS: Coital dynamic simulation 
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*The only comparison between CDS vs. no CDS that yielded p-value<0.05 was DCmax for RF 
(p=0.035) 
P-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum test; 




















Table 4.  Comparison of the pharmacokinetic-distance parameters of the virus surrogate (Tc-
Sulfur colloid) and drug surrogate (In-DTPA) in centimeter by product at 2 hours after dosing; 
median (25th percentile, 75th percentile) 
 




VF vs. RF 
P-value 
VF vs. RGVF 




















0.64 0.28 0.42 

















0.64 0.95 0.56 




















0.64 0.28 0.56 

















0.91 0.41 0.3 
Note: The coccyx is the reference point for all the distance variables above. 
Dmax: furthest point where radiosignal was detected; DCmax: distance at maximum 




*, **: Comparison of Dmin for Tc and In for RF, p=0.004, and RGVF, p=0.002 
P-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum test; 























Table 5a.  111In-DTPA permeability parameters by product (plasma). Median (25th percentile, 
75th percentile) 










Cmax ( curie/ml)(E-08)                                 

























0.75 0.021 0.030 
 Tmax(hr)       



























0.31 0.34 0.71 
AUC 
( curie.hr/ml)(E-06) 


































0.83 0.021 0.023 
 
SURAI: Simulated unprotected receptive anal intercourse; *Comparison of Cmax for SURAI vs. 
no SURAI for RF formulation: p=0.03 
 
P-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum test; 








Table 5b.  111In-DTPA permeability parameters by product (urine); median (25th percentile, 
75th percentile) 






































0.53 0.036 0.021 
 






















0.46 0.027 0.016 
% recovered     






















0.14 0.046 0.009 
SURAI: Simulated unprotected receptive anal intercourse; Max rate: maximum observed 
excretion rate; AURC: Area under the urinary excretion rate curve from 0 to last measurable 
rate; % recovered: Percent of initial dose of 111In-DTPA recovered in the urine 
P-values derived from pairwise comparison of formulations using Wilcoxon Rank Sum test; 






























Figure 3a. Median plasma TFV concentration (log-transformed) for each time point by product 
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Chapter 3: CHAMR 01 Study 
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CHARM-01 characterized the safety, acceptability, pharmacokinetics (PK), and 
pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application: the vaginal 
formulation (VF), the reduced glycerin vaginal formulation (RGVF) and the rectal specific 
formulation (RF) gel. The focus of this thesis is the comparison of the compartmental PK 
obtained from the six matrices: plasma, peripheral blood mononuclear cells (PMBC), colonic 
tissue, colonic mucosal mononuclear cells (MMC), rectal and vaginal fluid. CHARM-01 extends 
the objectives of CHARM-02 to multiple dosing and includes tissue drug concentrations, but 
does not include the colonic luminal imaging used in CHARM-02. 
Methods 
Participants received 4 mL of the three TFV gels in a blinded, crossover design: seven daily 
doses of RGVF, seven daily doses of RF, and six daily doses of placebo followed by one dose of 
VF, in a randomized sequence. Colonic tissue, blood samples, rectal and vaginal fluids were 
obtained before any rectal dosing (baseline) and thirty minutes after the 7th dose. In addition, 
blood samples, vaginal and rectal fluid samples were obtained at 2,4 and 24 hours after the 
final dose.  
Results  
TFV moieties were detected in all matrices except for PBMC; all concentrations of TFV-DP in 
PBMC were below the lower limit of quantification. There were no differences between RF and 
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RGVF in terms of TFV PK profile in plasma, rectal tissue homogenate, vaginal and rectal fluid.  
Median tissue mucosal mononuclear cell (MMC) TFV-DP trended higher for RF when compared 
to RGVF, 1136(IQR: 473-2200) and 320(IQR: 170-1150) fmol per 10^6 cells, respectively; 
however, this difference did not reach statistical significance (p=0.067).  
Conclusion 
There were no statistically significant differences between the PK features of TFV in RF and 
RGVF in plasma, rectal homogenate, colonic MMC, rectal and vaginal fluid.  
There was a trend of higher colonic MMC in RF as compared to RGVF, which did not reach 
statistical significance. Because participants received only a single VF dose, PK after VF dosing 
















Men having sex with men have a disproportionate burden of HIV globally. Part of the reason for 
such high prevalence is that the risk of contracting HIV is significantly higher in those that 
practice unprotected receptive anal intercourse (RAI)72-74. Hence, in addition to current 
biomedical and behavioral prevention strategies, rectal microbicides will provide an additional 
prophylactic method.   
 
One essential feature for rectal microbicide development is the ability of the candidate RM 
formulation to be present at a concentration that will inhibit infection at the site at risk of HIV 
infection.  As stated earlier, local dosing has the benefits of attaining higher drug concentration 
at the mucosa compared to systemic dosing21,56. In CHARM-01, we compare the concentration 
of TFV and its moieties in six matrices, namely, plasma, PBMC, colonic tissue, colonic MMC, 
rectal and vaginal fluid.  
 
Ethics Statement 
The study was designed by the investigators with collaborative input from CONRAD and the 
NIAID/DAIDS/Prevention Sciences IPCP for HIV Topical Microbicides, as stipulated in the award 
notice and reviewed by the U.S. Food and Drug Administration (FDA). The study was approved 
by the University of Pittsburgh Institutional Review Board (IRB) as well as the University of 
California at Los Angeles IRB. All subjects provided written informed consent. The trial is 
registered at ClinicalTrials.gov, number # NCT01575405 and is in compliance with the CONSORT 




Materials and Methods 
 The CHARM-01 study was a Phase 1, double blind, randomized crossover trial in which 
participants received the three TFV gel formulations (VF, RGVF, and RF) in a randomized 
sequence. Each phase of product administration lasted 7 days with a 21 (± 7) day washout 
period (Figure 1). The first and seventh doses of study product were administered in the clinic 
and the remaining five doses were administered by the participant at home, with daily, 
protocol-defined reminders to encourage product use.  
 
During the RGVF and RF phase of dosing, participants received seven identical doses of either 
the RGVF or RF TFV gel. However, during the VF phase of dosing, participants received six doses 
of a hydroxyethyl cellulose (HEC) placebo gel, with only a final dose of VF TFV gel. As the 
majority of participants in the RMP-02/MTN-006 rectal safety trial who received VF TFV gel 
experienced gastrointestinal side effects (bloating, abdominal discomfort, and diarrhea), it was 
considered unethical to ask participants to use more than one dose of VF TFV gel56.   
 
The study was conducted at two clinical sites (The University of Pittsburgh, Pittsburgh, 
Pennsylvania. and the David Geffen School of Medicine, University of California at Los Angeles, 
Los Angeles, California). Enrollment began in March 2013 and the last participant completed 
the study in October 2013. The target sample size was 18 (nine participants at each site) and 
enrolled participants were assigned at random to one of the three study formulation 
sequences. Randomization was done in blocks of three at each site to ensure balance between 
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formulation groups and the sequence of administration between sites.  The randomization 
scheme was stratified by site and generated by the University of Pittsburgh, Center for 
Research on Health Care Data Center, using computer-generated random numbers. The role of 
HH was the pharmacokinetic and pharmacodynamics data analysis and interpretation.  
 
The randomization assignments for up to 12 participants (24 total per site) were delivered to 
the Director of Pharmacy Affairs at the Magee-Womens Research Institute (MWRI) who held 
primary responsibility for maintaining the blinding and generated the product labels.   
 
Study population 
The study population consisted of healthy, RAI-abstinent, HIV-uninfected, adults (male and 
female) aged 18 years or older at time of screening who had been successfully vaccinated for 
hepatitis B virus (HBV) or who had naturally acquired immunity to HBV, as evidenced by HBV 
antibody titers. An inclusion criterion for female participants was the active use of an 
acceptable form of contraception (e.g., barrier method, intrauterine device, hormonal 
contraception, surgical sterilization, or vasectomization of the male partner). Individuals with 
abnormalities of the colorectal mucosa, significant gastrointestinal symptoms (such as a history 
of rectal bleeding), evidence of anorectal Chlamydia trachomatis (CT) or Neisseria gonorrhea 
(GC) infection, chronic HBV infection, or a requirement to use drugs that were likely to increase 






The VF TFV gel, the RGVF TFV gel, and the Universal HEC placebo gel were manufactured, under 
direction from CONRAD (Arlington, VA),  by DPT Laboratories (San Antonio, TX). DPT 
Laboratories generated pre-filled RGVF applicators and packaged the RGVF device with a 
plunger. DPT Laboratories also manufactured the RF TFV gel under direction of Dr. Lisa Rohan’s 
Group at MWRI.  The HTI applicators (HTI Plastics, Lincoln, NE) were used in the CHARM-01 
study. These applicators had been initially designed for vaginal use and have been used in all of 
the previous vaginal microbicide trials with TFV gel. They have also been used rectally in the 
RMP-02/MTN-006 and MTN-007 studies42,56. Each opaque pre-filled applicator was packaged 
with a plunger and labeled with a code to preserve the identity of the formulation.  Each pre-
filled applicator contained a dose of approximately 4 mL of TFV gel of the HEC placebo. The pre-
filled applicators were shipped directly to study site pharmacies and were stored by and 
dispensed from the site pharmacy. 
 
Each participant was assigned applicators based on the randomization number.  At Visits 3, 6, 
and 9, the participant’s first dose of study product was administered by the clinical staff. During 
the period of daily administration, study participants were instructed to insert one dose of gel 
into the rectum once daily throughout the seven-day period.    
 
Study procedures 
There were a total of eleven study visits and one follow-up phone call. After obtaining informed 
consent all participants were screened with a thorough medical history, a targeted physical 
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examination, a digital rectal examination, and rectal swabs for CT/GC nucleic acid amplification 
testing (NAAT).  Urine was also collected for CT/GC NAAT and for pregnancy testing in the 
female participants (pregnancy testing was repeated at all subsequent clinical visits). Blood was 
collected for safety labs (complete blood count, urea nitrogen, creatinine, alanine 
aminotransferase, and aspartate aminotransferase) and serology (syphilis, HIV-1, hepatitis B, 
and herpes simplex 1 and 2). Participants who met the aforementioned inclusion criteria during 
the Screening Visit were enrolled into the study. The Enrollment Visit occurred within 28 days 
of screening. At the Enrollment Visit, participants were randomized, and a rectal examination 
and focused physical examination were performed. Rectal swabs were collected for CT/GC. 
Rectal sponges for PK were also collected. Participants then received a normal saline pH 7.4 
enema. A flexible sigmoidoscope was inserted into the rectum and biopsies were collected at 
approximately 15 cm from the anal verge.  At Visits 3, 6, and 9 (Treatment Initiation Visits), all 
participants had a single applicator of study gel inserted into the rectum. Within 30 minutes, 
samples were collected for CT/GC. At Visits 4, 7, and 10 (Last Dose Treatment Visits), a normal 
saline enema was then administered followed by a single dose of study product.  Approximately 
30 minutes later (± 15 minutes) blood, and in females, self-collected vaginal sponges were 
collected for PK studies. A sigmoidoscope was then inserted and the same rectal tissue biopsy 
samples were collected as described during the Enrollment Visit (with the exception of samples 
for GC/CT and cytokines).  Additional blood and rectal/vaginal sponges were collected at 2 
hours (± 30 minutes) and 4 hours (± 30 minutes) after product insertion.  At Visits 5, 8, and 11 
(conducted 18-30 hours after Visits 4, 7, or 10) blood and rectal/vaginal sponges were collected 







Pharmacokinetic procedures  
Blood plasma, peripheral blood mononuclear cells (PBMCs), vaginal and rectal fluid, and 
rectal tissue were obtained before rectal dosing (Visit 2) and 30 minutes after the seventh 
dose of the gels (Visits 4, 7, and 10). Additional samples of blood plasma, PBMCs, and 
rectal/vaginal fluid samples were obtained at 2, 4, and 24h after the final dose (Visits 5, 8, 
and 11). 
 
Sample Processing: TFV and TFV-DP concentrations were determined via validated liquid 
chromatographic-tandem mass spectrometric (LC-MS/MS) methods at The Johns Hopkins 
University Clinical Pharmacology Analytical Laboratory as described previously [23].  All 
assays were validated following the recommendations of the FDA, Guidance for Industry: 
Bioanalytical Method Validation guidance document [10]. TFV concentrations were 
determined in plasma, rectal fluid, and vaginal fluid.  TFV-DP concentrations were 
determined for PBMCs, rectal tissue homogenates, and rectal MMCs. The measured value 
from each PK assay was used unless the PK value was determined to be between the lower 
limit of quantification (LLOQ) and the lower limit of detection (LLOD), in which case, a 





Analysis of outcomes 
Pharmacokinetics: TFV-based gel formulations’ PK were evaluated in six compartments 
(plasma, PBMCs, rectal fluid, rectal tissue, rectal MMCs, and cervicovaginal fluid) after rectal 
administration of the study product. For matrices other than tissue which were sampled 
multiple times after the last dose, the 24 hour post-dose concentration vs. time profile was 
examined for the final rectal dose of each TFV-containing study product (after 7 doses for RF 
and RGVF, after 1 dose for VF); TFV (or TFV-DP in PBMCs) maximum concentration (Cmax), time 
to maximum concentration (Tmax), and area under the TFV concentration-time curve from 0 to 
24h (AUC0-24 [log-linear trapezoidal method]) was estimated using non-compartmental methods 
(WinNonlin v. 6.3 software, Pharsight, St. Louis, MO).   Rectal biopsies, which were sampled 
only once with each product, were taken 30 minutes after each final study product dose to 
determine TFV and TFV-DP concentrations in tissue homogenates and TFV-DP in MMCs. We 
performed paired comparisons between RF and RGVF using the Wilcoxon rank sum test with 
exact two-sided significance test ( p < 0.05). VF was not compared due to non-steady state 




Enrollment and retention 
A total of 14 participants (11 men and 3 women) were enrolled and randomized in the study 
(Figure 2), 12 of whom completed the study. The majority of participants were white (57%) with 
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a mean age of 37.7 (± 14.3) years (Table 1). There was no statistical difference between sites in 
gender composition or the proportion of white participants, although there was a marginal 
difference with respect to age (41.7 versus 23.0; p=0.0414) with UCLA having a slightly older 
cohort. One female participant was enrolled but developed pyelonephritis prior to product 
exposure and was removed from the study. A second participant was randomized to receive the 
RGVF gel as the first study product. The participant completed Visit 5 but was subsequently 
withdrawn due to gastrointestinal symptoms including bloating and abdominal discomfort 
suggestive of irritable bowel syndrome. All other participants completed the study.  Averaged 
across all study visits, the proportion of completed administrative procedures, clinical 
procedures, clinical laboratory sample collection, and research laboratory sample collection 
was 89%, 87%, 96%, and 86% respectively. 
 
Pharmacokinetics 
TFV moieties were detected in all compartments sampled, except for PBMC TFV-DP which was 
below the LLOQ for all products (Table 3). The plasma TFV concentration-time profile (figure 3), 
Cmax, Tmax, and AUC0-24 were not significantly different for the RF and RGVF products (Table xx). 
There were no differences between RF and RGVF in TFV or TFV-DP in rectal tissue homogenate, 
though tissue MMC TFV-DP trended toward greater values with RF when compared to RGVF 
with median (IQR) RF/RGVF ratio of 1.8 (0.4, 3.9) (p=0.07). As mentioned previously, only a 
single exposure (Day 7) of the VF TFV 1% gel was given to those during their randomization to 





Rectal exposure to study products was associated with the detection of TFV in plasma, rectal 
fluid, and rectal tissue and TFV-DP in rectal tissue and tissue MMC but not in PBMCs. As 
previously reported, rectal exposure to TFV gels was also associated with detection of TFV in 
vaginal fluids.  
 
 
The compartmental PK data from CHARM-01 are similar to PK data generated in the RMP-
02/MTN-006 study (Yang PLOS ONE 2014): rectal exposure to TFV gels is associated with 
minimal systemic exposure, lack of drug detection in PBMCs, high concentrations in rectal 
tissue/fluid, and detection in vaginal fluid. MMC TFV-DP trended toward ~2-fold greater 
concentrations following RF when compared to RGVF. Otherwise, there were no PK differences 
between these two products.  
 
Single dose VF PK values cannot be fairly compared to the drug accumulation in steady-state RF 
and RGVF PK values after 7 doses. For example, based on our single dose VF PK data and the 
long TFV and TFV-DP half-life within most of the matrices tested [30], accumulation of TFV and 
TFV-DP after 7 daily VF doses would match or exceed the concentrations seen with the RF and 
RGVF products in this study.  
 
The CHARM-01 PK data do suggest that the RF formulation may deliver higher local 
concentrations of TFV-DP to the rectal mucosa than the RGVF formulation, although this did not 
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reach significance. This is the only discriminating parameter between the RF and RGVF TFV gels 
in the CHARM-01 study and may be insufficient to displace the RGVF TFV gel that is currently 
being evaluated in an International Phase 2 expanded safety study (MTN-017; ClinicalTrials.gov 
Identifier: NCT01687218) being conducted in the United States, Peru, Thailand, and South 
Africa. The results of the MTN-017 study (expected in early 2016), with approximately 192 
participants, eight week periods of exposure to daily or pericoital RGVF TFV gel, as well as a 
PK/PD substudy of 36 participants, will have a critical role in defining the future for the RGVF 
TFV gel as a candidate rectal microbicide for Phase 3 safety and effectiveness trials. Certainly, 
with increasing rates of HIV infection in MSM and transgender women  there is an urgent need 
to develop new approaches for the prevention of HIV infection in these highly vulnerable 
populations. 
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(n = 11) 
PITT 
(n = 3) 
Overall  
(n = 14) 
Age  41.7 ± 13.6 23.0 ± 1.7 37.7 ± 14.3 
Male  9(81.82%) 2(66.67%) 11 (78.57%) 
Race    
White 6(54.55%) 2(66.67%) 8(57.14%) 
Black or African American 4(36.36%) 1(33.33%) 5(35.71%) 
American Indian or Alaska Native 1(9.09%) 0(0.00%) 1(7.14%) 
Hispanic    
No, not of Hispanic, Latino/a, or Spanish 
origin 
9(81.82%) 3(100.00%) 12(85.71%) 
Yes, Mexican, Mexican American, 
Chicano/a 
1(9.09%) 0(0.00%) 1(7.14%) 
Yes, Another Hispanic, Latino/a or 
Spanish origin 

















Table 2. Pharmacokinetic data are summarized as median 
                (interquartile range)* 
Matrix Moiety PK Units RF TFV RGVF TFV VF TFV 




         5.1  
    (3.3-6.2) 








PBMC TFV-DP  fmol/M All BLQ All BLQ All BLQ 
Colon 
tissue 























TFV Cmax ng/mL 8.1x10
5  
((1.8 -16) x105) 




  AUC ng*hr/
mL 
1.4 x106  
((0.45-2.9)x106) 






TFV Cmax ng/ 
sponge 
31, 220 133, 172 6, 12 
  AUC ng*hr/ 
sponge 
486, 3,499 922, 1,377 88, 29 
*No RF v. RGVF comparisons are statistically significant (all p>0.05, Wilcoxon rank sum test). VF 
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Background: There is a paucity of evidence regarding optimal dosing of anti-tuberculosis drugs 
in children. The aim of this study was to identify the pharmacokinetic parameters of first-line 
anti-tuberculosis drugs, and concentrations achieved, after the implementation of the 2010 
World Health Organization (WHO)-recommended pediatric dosages.  
Methods:  We conducted a prospective, observational pharmacokinetic study in children 10-
years old, or younger, who were on isoniazid, rifampin, pyrazinamide, and ethambutol therapy 
in Durban, KwaZulu-Natal, South Africa.  Blood was collected at six time points over a 24-hour 
period, chosen using optimal sampling theory. Drug concentrations were simultaneously 
modeled to identify the compartmental pharmacokinetics of each drug in each child, using the 
ADAPT program.   
Results:  The best six sampling time points in children were identified as 0 (pre-dose), 0.42, 
1.76, 3.37, 10.31 and 24 hours post dose. Thirty-one children were recruited and blood drawn 
at these time points. Rifampin, ethambutol and pyrazinamide were best described using a 1-
compartment model, while isoniazid was best described with a 2-compartment model. Only 
9.6%, 83%, 64.5% and 30.7% of children attained the WHO 2-hour target therapeutic 
concentrations of rifampin, isoniazid, pyrazinamide, and ethambutol, respectively. Moreover, 
only 77%, 19%, and 26% achieved the area under concentration-time curves associated with 
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optimal clinical response of rifampin, pyrazinamide, and isoniazid, respectively. No single risk 
factor was significantly associated with sub-therapeutic drug levels. 
Conclusion: Drug concentrations of all first line anti-tuberculosis drugs were markedly below 
the target therapeutic concentrations in most South African children who received the revised 




Tuberculosis (TB) continues to be a major global public health threat in which children bear a 
significant portion of disease mortality and morbidity. In 2012, there were an estimated 8.6 
million new cases worldwide, with most cases in several high-burden countries including South 
Africa, China, India and Russia. In South Africa, childhood TB accounts for 15-20% of the burden. 
To compound this, the additional problem of multidrug resistant TB (MDR-TB)-, extensively- 
and totally-drug resistant strains has emerged.1, 2 Despite these ominous threats, the first-line 
treatment regimen for TB, comprised of isoniazid, rifampin, pyrazinamide, and often 
ethambutol, has remained stagnant for several decades. With the failure to ensure adequate 
control of the childhood TB burden, an evaluation of drug concentrations associated with 
standard dosing of the existing drugs is paramount, since inadequate drug levels may 
contribute to treatment failure and the problem of MDR-tuberculosis.2  
 
The design of pediatric pharmacokinetic (PK) studies needs to be optimized. Often, pediatric PK 
studies have relied on a convenience sampling strategy, and a desire to incorporate the 2hr 
time point. However, this “random” and arbitrary sampling strategy leads to imprecision in PK 
estimation, and is a common source of error.3-5 First, there is need to define the full 
concentration-time profile over a dosing interval so that AUC0-24, Tmax, and Cmax can be 
identified, which always vary from child to child. Specifically between-individual PK variability is 
a fact that must be taken into account in study design. Second, the duration of sampling is most 
accurate when the sampling time encompasses at least three elimination half-life values for all 
drugs.4 An approach that takes these concerns into account is application of optimal sampling 
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theory, based on Fisher information matrix.3, 5 Blood draws are performed at particular 
“information rich” time points, allowing for identification of unbiased PK parameter estimates. 
The number of sampling times is also minimized, without loss of information since sampling 
occurs at points that maximize useful information. Here, we applied optimal sampling theory to 
the sampling strategy design so that more accurate PK parameter estimates could be identified 
in children. 
 
The importance of accurately identifying PK parameter estimates in children is to ensure that 
optimal dosing strategies can be designed. An optimal dose is that which achieves a target 
concentration that is known to be associated with optimal microbial and clinical outcomes. The 
most commonly utilized reference concentrations by the WHO have been 2hr drug 
concentrations, with references of rifampin 8 mg/L, isoniazid 3 mg/L, pyrazinamide 20 mg/L, 
and ethambutol 2 mg/L.6  In order to achieve these target 2hr drug concentrations, the WHO 
recently recommended new treatment doses for children.7 These 2hr concentrations are often 
confused with “peak” (Cmax) concentrations, however McIlleron et have shown that they differ.
8 
Moreover, 2hr concentrations have been found not to be predictive of clinical outcomes in 
several studies in adults.9-11 Furthermore, these 2hr concentrations were not designed to 
address the question of acquired drug resistance (ADR); ADR is unquestionably driven by low 
drug concentrations, which initiate a series of molecular events termed “the antibiotic 
resistance arrow of time”.11-22 On the other hand, studies in the hollow fiber model (HFM) and 
in murine TB, and our re-analysis of older guinea pig studies, have identified that instead it is 




The HFM studies and computer-aided clinical trial simulations predicted that PK variability was 
the main driver of therapy failure and ADR in South Africa.11 This was confirmed in three 
studies, first a meta-analysis of prospective studies that involved 2,382 patients, and later in 2 
prospective clinical studies.12, 13, 25 In one  clinical study of 142 adult South Africans, >90% of 
therapy failure (death, relapse and microbial failure) and 100% of ADR was explained by having 
a pyrazinamide AUC0-24 ≤ 363 mg·h/L, a rifampin AUC0-24 ≤13 mg·h/L and an isoniazid AUC0-24 
≤52 mg·h/L, as well as low Cmax.
12 These findings have since been validated in a separate 
prospective clinical study.25 Moreover, these concentration thresholds predictive of outcome in 
adult TB were virtually the same as identified in HFM and in mice.15-18, 22 Here, we investigated 
how often South African children treated with the new WHO recommended doses achieve the 
older reference concentrations used by the WHO as well as how often they achieved the AUC0-
24 thresholds that predicted clinical outcomes in adults. 
 
MATERIALS and METHODS 
Regulatory compliance 
The Institutional Review Boards (IRB) of the University of KwaZulu-Natal and Johns Hopkins 
University approved this study. 
 
Study Population and Setting 
Pharmacokinetics of Anti-Tuberculosis Medications in South African Children (PHATISA) is a 
prospective, single-center, observational PK study that was conducted at the King Edward VIII 
hospital in Durban, South Africa, from May 2012 to March 2013. Children 10 years of age or 
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younger with the diagnosis of TB were enrolled. The diagnosis of TB was based on clinical 
symptoms, radiological findings, tuberculin skin testing, history of household contact, and 
microbiologic confirmation. Children were excluded from the study if they had a hemoglobin 
level <6 grams per deciliter, alanine aminotransferase (ALT) more than 3 times the normal value 
for age, evidence of coagulopathy based on an abnormal PT/PTT, probable diagnosis of 
abdominal TB based on clinical findings, or any history of intolerance or allergy to the first-line 
anti-TB drugs. Children who were enrolled in another study were also excluded.  
 
Baseline clinical data was obtained for each participant, including age, nutritional status 
(weight, height, mid upper arm circumference), alkaline aminotransferase, creatinine, blood 
urea nitrogen (BUN), and chest radiography. HIV testing was performed by antibody testing for 
children older than 18 months of age, and by HIV DNA PCR for those younger than 18 months 




The diagnosis of definite TB was made if there was microbiological evidence (by sputum or 
tissue culture Mycobacterium tuberculosis positivity) or probably TB (by acid-bacillus smear 
positive and/or a classic radiological finding); those that did not meet these criteria but showed 
symptoms of TB (possible TB) and were started on treatment were also included in the study.26 
Children were started on standard first-line anti-TB agents, rifampin, isoniazid, and 
pyrazinamide with addition of ethambutol for severe forms of TB in accordance with the new 
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WHO guidelines. These guidelines recommend that children receive 10-15 mg/kg of isoniazid, 
10-15 mg/kg of rifampin, 30-40 mg/kg of pyrazinamide, and 15-25 mg/kg of ethambutol.7 
Informed consent was obtained from parents or guardians prior to enrollment. 
 
Drug treatments 
Drugs were provided by the hospital pharmacy and were obtained from Aspen Pharmacare and 
Sanofi-Aventis South Africa (Pty) Ltd. Drugs were ground and given as food emulsions for 
children too young to swallow tablets. The drugs were given as fixed dose combinations. The 
doses were rounded to the nearest value using the available tablet sizes: combined rifampicin, 
isoniazid and pyrazinamide 60,30 and 150 mg tablet, combined rifampin and isoniazid  60 and 
30 mg or 60 and 60 mg tablets, pyrazinamide 150 and 500 mg tablets, and ethambutol 100 and 
400 mg tablets according to weight based charts. 
 
Study and sampling procedures 
Blood samples were obtained from each participant between the fourth and twelfth day after 
initiation of anti-TB therapy. In order to avoid biased PK parameter estimation, optimal 
sampling theory was utilized to identify information-rich time points for each of the four drugs 
with the use of ADAPTII software.3-5, 27 Six time points were identified. Peripheral intravenous 
catheters were used for sample collections. At each time-point, 2-ml of blood was collected in 
EDTA-coated tubes. Each specimen was immediately placed on ice until processing.  Blood 
samples were centrifuged at 2,000 x g for 10 minutes. The plasma layer was separated within 




Drug concentration measurement assays  
Measurement of drug concentrations was carried out by a previously published multiplexed 
three-drug assay using liquid chromatography coupled to tandem mass spectrometry (AB-Sciex 
Qtrap® 4500 LC/MS/MS system).28 The internal standard was 6-amino nicotinic acid. Calibration 
and quality control standards, along with a blank plasma aliquot and an internal standard 
aliquot, were used for all runs. Dilutions of standard drug solutions were used to cover the 
range of concentrations expected for each drug. Three quality control solutions were used to 
span the range of serum drug concentrations: lowest (QL), intermediate (QM), and highest 
(QH). Inter-day and intra-day coefficients of variation were below 10%. Selected multiple 
reaction monitoring (MRM) transitions were run in positive ion mode of [M+H]+. Precursor ions 
to product ions were isoniazid (mass-to-charge ratio [m/z] 138.1 51.9), rifampin (m/z, 
823.1791.2), pyrazinamide (m/z, 124.1  52.1), and 6-amino nicotinic acid (m/z, 138.7 
58.9). Analyst® 1.5 software version 1.5.1 was used.  
 
Compartmental PK analyses  
All concentrations of rifampin, isoniazid, pyrazinamide, and ethambutol were modeled using 
the ADAPT 5 software program.29 First, we utilized the standard two stage estimation method 
to generate initial PK parameter estimates for each drug for a one-, two-, or three-
compartment model, with first-order input and elimination. The compartmental parameter 
estimates were then used in subroutine POPINIT of ADAPT. Next, each drug was modeled to 
identify pharmacokinetic parameter estimates for each child using the maximum-likelihood 
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solution via the expectation-maximization algorithm (MLEM). Choice of best compartmental 
model was then made based on lowest Akaike information criterion (AIC) score and Bayesian 
Information Criteria (BIC). While ideally they should agree, the BIC, which penalizes for 
complexity, was used for the final decision. However, we also applied the rule of parsimony, 
based on Occam’s razor, which was that if AIC and BIC chose the more complex model, but that 
model did not significantly improve the parameter estimates compared to the less complex 
model, then the simpler model offered the best explanation. 
 
Statistical analysis  
STATA version 12 was used for statistical analysis. The baseline characteristics and secondary PK 
parameters such as Cmax, Tmax, and AUC0-24 were summarized as means ± standard deviation. 
The 2hr concentration values were considered to be binary data: above the reference target 
concentration or below. The 2 hour reference concentrations for rifampin were 8 mg/L, for 
isoniazid 3 mg/L, for pyrazinamide 20 mg/L, and for ethambutol 2 mg/L, based on previous 
studies that utilized these concentrations to design new doses.30 These were used simply to 
identify if the intended target concentrations for the new WHO doses had been attained. Next, 
we wanted to identify the proportion of children in these WHO recommended doses who 
achieved or exceeded, the AUC0-24s shown to be associated with clinical outcome in pulmonary 
TB adult patients.12 These were a pyrazinamide AUC0-24 ≤ 363 mg·h/L, a rifampin AUC0-24 ≤13 
mg·h/L and an isoniazid AUC0-24 ≤52 mg·h/L. For this latter analysis the concentrations were not 




For each of the four drugs, the Cmax and AUC were dose-normalized, depicted as Cmax/D and 
AUC0-24/D, respectively. Graphical exploratory data analysis showed that the Cmax and AUC0-24 
were not normally distributed; hence, non-parametric tests were used to investigate 
differences in  Cmax and AUC among the covariates. The Wilcoxin rank-sum test was used to 
delineate differences in Cmax/D and AUC0-24/D between younger and older children (<2 years vs. 
>2 years), sex (male vs. female), HIV serostatus (positive vs. negative), and nutritional status 
(malnourished vs. non-malnourished).  
 
RESULTS 
Application of optimal sampling theory revealed that the best six sampling time points in 
children were 0 (pre-dose), and 0.42, 1.76, 3.37, 10.31 and 24 hours post dose. These sampling 
times were then used to time blood draws. A total of 36 children, treated between May 2012 
and March 2013, were eligible for the study. Three parents declined informed consent. One 
patient improved with antibiotic therapy for bacterial pneumonia and the clinical diagnosis of 
probable TB was removed with discontinuation of anti-TB therapy. Another patient was 
diagnosed with probable gastrointestinal TB after imaging, and was disqualified from the study. 
The baseline anthropometric and clinical data in the 31 remaining children is summarized in 
Table 1. 80.6% children presented with pulmonary tuberculosis; 19.4% had disseminated 
disease.  
 
All children were inpatients and doses were received under supervision of nurses; however 11 
children received their doses as outpatients. Dosages received by participants for each of the 
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four drugs were ascertained by checking the bottles of the drugs as well as the prescribed 
dosage in the participants’ charts (Figures 1-4, Panel A). Overall, 90.3% (28/31), 83% (26/31), 
41.9% (13/31), and 84.6% (11/13) of participants received dosages within the revised WHO 
recommendations for rifampin, isoniazid, pyrazinamide, and ethambutol, respectively (Figures 
1-4, Panel A). 
Spearman’s rank correlation coefficient was used to determine if correlations existed between 
underdosing of one drug and another. This evaluation revealed a strong statistically significant 
correlation between underdosing of isoniazid and rifampin (ρ=0.746, p-value 0.001), isoniazid 
and pyrazinamide (ρ=0.373, p-value 0.039), but not between rifampin and pyrazinamide 
(ρ=0.278, p-value 0.13). This correlation reflects the fact that fixed dose combinations were 
used, an effect compounded by weight banding. 
 
Rifampin, pyrazinamide, and ethambutol were best described using a one-compartment model, 
while isoniazid was best described using a two-compartment model. The mean population PK 
parameter estimates for all four drugs are shown in Table 2. Secondary PK estimates such as 
Cmax, 2hr concentrations, and AUC0-24, are shown in Figures 1-4, which highlight the wide inter-
patient variability for each of the drugs.  Table 3 shows how poorly either the 2hr concentration 
and Cmax were as predictors of AUC0-24. The r
2 were mediocre, except for pyrazinamide which 
had a moderate r2. The duration of therapy until blood draws for drug concentration 
measurement was a median of 7.0 (range:4-12) days. The relationship between duration of 
therapy and drug concentration is shown in Table 4, which shows none of the slopes 
significantly differed from zero. Thus, the duration of therapy until blood draws for the PK study 
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was not associated with low or high serum drug concentration, even for rifampin which 
undergoes autoinduction. 
 
Table 5 shows a summary of the proportion of children who achieved the reference 2hr drug 
concentrations that has been used for dose design in children. For all four drugs, a substantial 
portion of children achieved 2hr concentrations below the reference targets, especially 
rifampin and pyrazinamide. This means that for children in KwaZulu, the new WHO 
recommended doses still fail to achieve their intended target concentration. Table 4 also shows 
that median value and range of 2hr concentration differed from those for Cmax for all drugs, 
except the pyrazinamide median (but not range).  
 
Table 5 also shows that for isoniazid and pyrazinamide, most children did not achieve the  
AUC0-24 that have been shown to be associated with optimal long term responses such as cure 
in adults. In the case of rifampin, a recent clinical study in adults identified a rifampin AUC of 35 
mg*h/L as predictive of speed of sterilizing effect and 2-month sputum conversion rates.25 
Twenty-two (71.0%) of the 31 children had a rifampin AUC≤35 mg*h/L, which suggests they 
would have slow sterilizing effect rates and delayed cure. Thus, overall, rifampin, isoniazid and 
pyrazinamide exposures were below optimal AUC0-24 in a majority of the children. 
 
Next, we performed a univariate analysis for failure to achieve target 2hr drug levels for each of 
the four study drugs against clinical and demographic factors,  only HIV positivity was 
significantly associated with low 2hr/D for isoniazid (p = 0.04, Wilcoxon rank sum comparison). 
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There was a trend towards significance for low AUC0-24/D for isoniazid and pyrazinamide (p = 
0.07 for both drugs).  
 
DISCUSSION 
There are several findings in our study. First, we evaluated the plasma concentration of the four 
first-line anti-tuberculosis drugs that are achieved in children dosed according to the 2010 
revised WHO dosing recommendation. The most important finding in our study was the 
surprisingly high proportion of children with sub-therapeutic plasma concentrations of all four 
drugs, even in those receiving recommended revised WHO dosages. Our PK parameter 
estimates and drug concentrations are likely accurate and have minimal bias, given that we 
employed optimal sampling theory to identify the most information rich sampling times, as 
opposed to a design based on convenience. Our findings  suggest a need to increase the doses 
of these drugs in children above what is currently recommended by the WHO. On the other 
hand however, the target concentrations used to make this recommendation assume that the 
2hr and AUC concentrations needed for optimal effect in adults are the same as in children. 
This is currently unknown and should be investigated, given possible differences in bacterial 
burden between adults and children with tuberculosis.31  
 
Secondly, the PK parameter estimates in the children we studied differed from those from 
other parts of sub-Saharan Africa and from India.32, 33 A study from Cape Town, South Africa, 
reported different AUCs and Cmax concentrations in children who received the revised WHO 
recommended doses. As a result, the proportion of children who achieved sub-therapeutic drug 
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concentrations was lower than in our current study. Both studies are correct, and the 
differences simply illustrate the large between-patient PK variability in children between 
different regions of the same country, perhaps due to genetic, demographic, and nutritional 
factors as well as co-morbities. Our current study was conducted among children primarily of 
Zulu ancestry, who also had a wider age range (3 months to 10 years, with 48% being > 2 years 
of age) compared to the Cape Town study.32, 33 Indeed, in a study of ofloxacin in adults from the 
same two places, PK parameter estimates differed between them in MDR-TB patients.34 
Similarly, PK parameters and their variability are expected to differ in children in different 
countries. This variability strongly emphasizes the crucial need to establish population PK 
parameter estimates in children in each different locale where there is a large pediatric 
tuberculosis burden: children in Mumbai differ from those in KwaZulu-Natal who differ from 
those in Cape Town. Our findings should be used to allow more targeted local adjustment of 
doses by clinicians. 
 
In summary, despite implementation of the 2010 WHO dosing guidelines, a considerable 
proportion of children still achieve sub-therapeutic anti-TB drug concentrations. Since 
metabolism of each of the drugs is from different xenobiotic metabolism enzymes encoded by 
unlinked alleles, the subtherapeutic concentrations observed across all four drugs suggest that 
dosing practices (in this case in pursuance of WHO guidelines) is one of the major reasons for 
the low drug concentrations, and not pharmacogenetic reasons. The current practice of 
prescribing first-line TB drugs is weight-based; hence, a 2-month old infant will receive the 
same 10 mg/kg dose of INH as a 10-year old child. This approach ignores the significant 
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physiologic differences that exist between infants and children, in addition to the weight 
difference. As an example, principles of allometric scaling, such as the ¾ power laws mean that 
children of different weights should be dosed differently based on different mg/kg doses.35-38 In 
other words, a 10 mg/kg dose in a 5 kg infant (50 mg) will achieve different concentrations in a 
30 kg child who is ten years old (300 mg) because the effect of weight on clearance and volume 
is non-linear. Thus, further well-powered studies are needed to elucidate optimal age- and 
weight-based dose schedules in the pediatric population. In addition, studies that also compare 
the clinical responses in children with and without sub-therapeutic levels are needed to further 
inform and strengthen the underlying concern that failure to achieve the therapeutic targets in 
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Table1. Baseline demographics and clinical characteristics 
Clinical factor Median (range) 
Demographics  
Age, years 
       ≤ 2 years, n 




Weight, kg 11.5 (6.1-19) 
Height, cm 84 (66-114) 
Malnourished, n (%) 20 (64.5) 
HIV+, n (%) 7 (22.6) 




Hemoglobin, g/dL 9.2 (7-11.7) 




Microbiologic Data, n 
       Smear positive 
       Culture positive 
       Hain positive 







Diagnostic Data  
Positive TST, n** 13/17 
Chest X ray findings, n 
      Cavitary lesion 
      Parenchymal consolidation 






























Total clearance (L*hr-1) 12.2 (7.58) 12.7 (9.9) 2.7 (0.9) 20.6 (6.1) 
Volume of central compartment (L) 56.4 (7.5) 85.1 (42.7) 24.0 (2.3) 135 (21.2) 
Absorption constant (hr-1) 10.0 (4.4) 14.8 (7.4) 0.9 (0.3) 1.7 (2.1) 
Inter-compartmental clearance (L*hr-1) 
 
10.2 (2.8) NA NA  
Volume of peripheral compartment (L) 1.0 (0.3) NA NA  






























Table 3. Concentrations achieved in South African children treated with World Health 
























Observed 2-hour concentration 











14 (45%) 29 (94%) 11 (35%) 11 (85%) 
     
Pharmacokinetic model derived peak 
Median (range); mg/L 
 
22.51 (11.18-47.17) 3.47 (0.56-
10.20) 
6.05 (1.83-10.28) 1.44 (0.62-6.28) 
Pharmacokinetic model derived AUC0-24 
Median(range); mg*h/L 233.9 (110.10-
525.7) 
21.2 (1.8-67.3) 28.7 (6.8-153.0) 10.8 (4.7-22.7) 
Children with AUC0-24 
below optimal (%) 










The p-values are for the D'Agostino and Pearson omnibus normality test, whereby a 





a. Isoniazid doses administered are compared to the WHO recommended doses. 
The majority of patients were dosed according to the WHO recommended doses. The 
ratio between the highest and lowest dose administered was 4.7. 
b. Isoniazid 2hr concentration had a lowest-to-highest ratio of 14.7, several fold 
higher than that imposed by dose. The true time to peak concentration (Tmax)  had a 
median and range of 1.75 (0.33-3.67) hrs, indicating a wide variability in Tmax, and that 
the 2hr concentration rarely coincided with isoniazid peak concentration in the children.  
c. Isoniazid peak concentration differed from the 2-hour concentration in 
distribution. The ratio between the lowest and highest peak was 5.6, closely tracking the 
doses administered.  
d. The isoniazid AUC0-24  achieved varied 22.5-fold between the lowest and highest, 



















A p≥0.05 is significant for a normal distribution. 
a. The ratio of the lowest-to-highest rifampin dose was 2.5-fold, and mostly was either 
in the WHO recommended doses or even higher.  
b. Rifampin 2hr concentration had a lowest-to-highest ratio of 308.3, more than 100-




c. Rifampin peak concentration had a lowest-to-highest ratio of 18.2, and thus lower 
than the variability of the rifampin 2-hr concentration. 
d. Rifampin AUC0-24  achieved varied 37.8-fold between the lowest and highest. More 






























A p≥0.05 is significant for a normal distribution. 
a. The ratio of the lowest-to-highest pyrazinamide dose was 2.8-fold, with a large 
proportion below the WHO recommended doses.  
b. Pyrazinamide 2hr concentration had a lowest-to-highest ratio of 28.3, several fold 
higher than ratio for the dose.  
c. Pyrazinamide peak concentration had a lowest-to-highest ratio of 4.2, and thus lower 
than the variability of the pyrazinamide 2-hr concentration. 
d. Pyrazinamide AUC0-24  achieved varied 4.8-fold between the lowest and highest 












A p≥0.05 is significant for a normal distribution. 
a. The ratio of the lowest-to-highest ethambutol dose was 2.5-fold, with a large 
proportion below the WHO recommended doses.  
b. Ethambutol 2hr concentration had a lowest-to-highest ratio of 139.1, >100-fold 
higher than ratio for the dose.  
c. Ethambutol peak concentration had a lowest-to-highest ratio of 4.3, and thus lower 
than the variability of the ethambutol 2-hr  concentration. 
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Chapter 5:  Conclusion 
 
Pharmacokinetic analysis is a vital part of drug development and optimization of 
therapeutic regimens.  In this thesis, the role of systemic and local quantitation of 
tenofovir after local (rectal dosing) was presented. In addition, utility of quantitative 
pharmacokinetic analysis to evaluate adequacy of therapeutic regimens currently 
recommended for clinical practice was evaluated in the setting of first-line anti-TB 
medications in a pediatric population where data-driven dosing regimen 
recommendations are lacking. 
 
1. Rectal Microbicide Development for Pre-exposure Prophylaxis 
1.1. Our Findings 
In CHARM-02, we found that all three candidate TFV 1% gel products were safe for one-
time dosing. There were more minor gastro-intestinal AEs during VF administration 
period. CHARM-02 also mainly focused on PK and evaluation of colonic distribution of 
three candidate TFV 1% gel products: We found that the hyperosmolal product, VF, has 
the greatest distribution (highest Dmax), and also, as inferred from the permeability and 
plasma TFV concentration data, is associated with the greatest permeability to small 




difference in co-localization of the drug and virus surrogate between these three study 
gels.    We also noted that all the differences seen in the colonic distribution between VF 
and the other two study gels becomes insignificant when dosing was followed by 
simulated coitus compared to no differences seen when dosing is not followed by 
coitus.   We believe PK with and without coitus are both relevant as some doses will not 
be followed by sex and some will, hence a combination of the sex/no sex differences 
may combine over time to generate persistent differences between products in a given 
individual. 
 
CHARM-01 looked at safety and multi-compartment PK after multiple (7-doses) doses of 
the RF and RGVF TFV 1 % gel, and single dose of VF gel. Daily dosing of the RF and RGVF 
gels for one week was found to be safe without any histologic evidence of tissue 
damage (data not included in the thesis, but presented in the published manuscript)59. 
The VF product was associated with increased minor AEs, significant, since this was with 
only a single dose compared to 7 doses for the other two products. Looking at the PK of 
TFV in plasma, rectal tissue, rectal and vaginal fluid and its active moiety, TFV-DP, in 
colonic MMC, PBMC, and rectal tissue, there were no statistically significant differences. 
Of note, the median concentration of TFV-DP in colonic MMC was numerically higher 
(but not quite statistically significant at the 5% level) for RF as compared to RGVF with 
median mucosal mononuclear cell (MMC) TFV-DP RF/RGVF ratio of 1.8 (interquartile 




between RF and RGVF, there were no major safety or PK differences between these two 
study formulations.  
 
Based on these two studies, we conclude that both RF and RGVF are safe to be 
advanced to phase II trials. Currently, MTN-017, a phase II clinical trial with RGVF is 
underway.  
 
1.2. Challenges and Future Directions 
 
One major challenge for HIV microbicdes is identifying the target TFV concentration that 
is protective from HIV infection in the pertinent compartment. This would require 
bridging studies that can relate concentrations from easily obtainable compartments, 
such as plasma, to concentrations that are less accessible, but more pertinent to 
assessing HIV infection, such as colonic/vaginal mucosa. In the CAPRISA 004 study, 
where women received coitally-depended TFV 1% gel, TFV concentration of at or above 
1000ng/ml in cervico-vaginal fluid was associated with increased protection from HIV. In 
the iPrEx study, where MSM were provided with oral emtricitabine/tenofovir as PrEP, a 
TFV-DP concentration of 16 fmol/million cells in PBMC was associated with increased 
protection17,75. In order to make sense of these concentrations, we need bridging 
studies that simultaneously measure concentrations of TFV and its active moiety in 
several compartments simultaneously, such as the CHARM-01 study, which looked at 




studies, we then will be able to integrate the information with pharmacodynamic data 
obtained from clinical trials to identify the target concentration for prevention of HIV 
infection.  Such a “connect-the-dots” exercise using data across studies is, however, 
subject to potential drift in PK across studies due to methodologic differences (analytical 
methods or population differences) that require attention to subtle differences and 
caution in application. It is most preferable to collect PK samples at all anatomic sites in 
at least, some subjects in seroconversion outcome studies to minimize known and 
unknown variables.  
 
Another challenge is our quantification of the distribution of the study gels. In CHARM-
02, we used SPECT/CT along with radiolabeled drug and virus surrogate to look at the 
distribution of the three study products. The main limitation of this method is that it 
only assesses the distribution of the study gels in the colonic lumen, but does not 
evaluate mucosal distribution, per se.  One potential method that may improve our 
ability to deliver more active drug to the mucosa is use of nanoparticles. With the 
advances in nanotechnology, novel mucus-penetrating nanoparticles are being 
investigated for mucosal drug delivery. For instance, Ensign,  et al., demonstrated 
vaginal delivery of a mucus-penetrating acyclovir formulation in mice which rapidly 
penetrates cervicobaginal mucus nearly as quickly as water76. In addition, 
nanoformulations coupled with imaging modalities such as fluorescence particle 
tracking technology will optimize our ability to quantify drug delivery via mucosal 




surface (100-1,000 micron resolution) than provided by SPECT/CT (3.54 millimeter 
resolution scale).  Using these microscopic imaging methods, these mucus penetrating 
nanoparticles are seen to provide a highly uniform distribution across the mucosal 
surface, in contrast to conventional particles which move more slowly through mucus 
and rest on the mucosal surface in very heterogenous patterns. Especially in a setting of 
coitally dependent microbicide use, both speed of mucosal contact and uniform 
mucosal surface distribution are preferred. Drug diffusion across the mucosal surface 
and into the tissue may well establish homogeneity of distribution in time, but coitally 
dependent dosing may not allow this time delay. To this end, anti-retroviral 
nanoforumulations for mucosal use, such as TFV, are being actively investigated77,78.  
 
Last, the success of any PrEP product will depend on acceptability and adherence to 
PrEP regimen. While there were multiple variables affecting adherence in the VOICE and 
Fem-PrEP studies, product acceptability was one of the relevant factors in its infrequent 
use and contributed to poor adherence, which hindered the studies’ ability to evaluate 
efficacy of the TFV as PrEP34,35. This also highlights the need for objective assessment of 
drug adherence such as using drug concentration as a reflection of drug use. Though this 
data was captured in the VOICE trial, TFV concentration in plasma samples was only 
collected quarterly and was not assayed until the study was complete. Having a more 
frequent drug level assessment available in real time may aid in providing objective 
measure of adherence to enable targeted adherence interventions.  Additional novel 







2. TB Therapy in Children 
2.1. Our Findings 
The results of the PHATISA study shows that even with the revised higher doses of first-
line anti-TB drugs, many children are achieving below target concentration for all of the 
drugs; this was particularly striking for rifampin, one of the backbones of TB therapy, 
with only 3 out of 31 children achieving the target concentration. Given RIF’s ability to 
develop resistance with just one single mutation and the fact that children will be 
treated with only INH and RIF for the continuation phase, it would  mean that children 
are receiving INH monotherapy during the continuation phase. For populations such as 
Kwa Zulu Natal, an epicenter for TB and HIV, and areas with high INH resistance, this 
may result in major treatment failures and possibly contribute to the already growing 
problem of mulit-, extensive, and totally-drug resistant TB.  
 
2.2. Challenges and Future Directions 
The paucity of data regarding optimal TB therapy in this population results in suboptimal 
therapeutic regimens in this vulnerable population. Given the major differences in 
immunology, bacterial burden and distribution of TB disease in adults and children, we 
need well-designed, well-powered pediatric studies that relate the PK of these first line 





Since the revised WHO pediatric dosing guideline came to effect in 2011, there have 
only been two studies, other than the PHATISA study, that evaluated the new dosing 
regimen79,80. Hence, well-designed, well-powered studies that relate PK of these first 
line drugs to clinical outcome (PD) are urgently needed.  
 
More importantly, as novel therapies for TB are being planned, we need children to be 
included in the studies so that more accurate dosing regimens, which take into account 
factors specific to the pediatric population, can be evaluated. Regulations such as the 
Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, which 
require pharmaceutical companies to include pediatric studies prior to submission for 



















1. McGowan I, Cranston RD, Duffill K, et al. A Phase 1 Randomized, Open Label, 
Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of 
Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). PLoS One. 
2015;10(5):e0125363. 
2. Anderson PL, Liu A, Buchbinder S, et al. Intracellular Tenofovir-DP Concentrations 
Associated with PrEP Efficacy in MSM from iPrEx (paper 31LB). Paper presented 
at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 
2012; Seattle, WA, USA. 
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV 
prevention in men who have sex with men. N Engl J Med. Dec 30 
2010;363(27):2587-2599. 
4. Ensign LM, Tang BC, Wang YY, et al. Mucus-penetrating nanoparticles for vaginal 
drug delivery protect against herpes simplex virus. Sci Transl Med. Jun 13 
2012;4(138):138ra179. 
5. Meng J, Zhang T, Agrahari V, Ezoulin MJ, Youan BB. Comparative biophysical 




nanoparticles intended for HIV prevention. Nanomedicine (Lond). Aug 
2014;9(11):1595-1612. 
6. Belletti D, Tosi G, Forni F, et al. Chemico-physical investigation of tenofovir 
loaded polymeric nanoparticles. Int J Pharm. Oct 15 2012;436(1-2):753-763. 
7. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure 
prophylaxis for HIV infection among African women. N Engl J Med. Feb 5 
2015;372(6):509-518. 
8. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP Trial of 
Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. 
N Engl J Med. 2012;(In Press). 
9. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and 
pyrazinamide in children younger than two years of age with tuberculosis: 
evidence for implementation of revised World Health Organization 
recommendations. Antimicrob Agents Chemother. Dec 2011;55(12):5560-5567. 
10. Kwara A EA, Gillani F, et al. Pharmacokinetics of First-Line Antituberculosis Drugs 
Using WHO Revised Dosage in ChildrenWith Tuberculosis With and Without HIV 












Hiwot Hiruy, MD 
 
Ph.D. Candidate 
Johns Hopkins School of Public Health 






Education and Training 
  
PhD   Bloomberg School of Public Health, Johns Hopkins 
University 
Sept ’12 – present Graduate Training Program in Clinical Investigation 
 
Fellow   Johns Hopkins University School of Medicine, 
Baltimore, MD 
July ’12 – Present Clinical Pharmacology 
 
July ’10 – July ‘13       Pediatric Infectious Disease 
 
Residency   Seattle Children's Hospital and Regional Medical Center  
July ’05 – July ’08 University of Washington 
 
MD   Johns Hopkins University School of Medicine, 
Baltimore, MD 
Sept. ’01 – May ’05  
 
BS Biochemistry University of Maryland at College Park, MD 
Aug ’98 – May ’01 
 
Pre-medicine  Montgomery College, Takoma Park, MD 
Aug ’96 – May ‘98  
 
 
Clinical Experience (International) 
 
Aug ’08 – July ’09 Pediatric AIDS corps physician, Kilimanjaro Christian 
Medical Center, Moshi, Tanzania 
  Provided care in HIV clinic, supervised as a consultant in the 
pediatric 
  Ward, mentored healthcare providers in outreach posts. 





                                   College of Medicine   
 
July ‘09 – May ‘10 Pediatric AIDS corps physician, Gondar University Hospital, 
Ethiopia 
Provided care in pediatric outpatient urgent care and TB 
clinic; taught didactic and clinical skills to medical students. 
 
Funded by Baylor International Pediatric AIDS Initiative, 






July ’13 – present Co-investigator, Johns Hopkins University School of 
Medicine, Baltimore, MD. 
Part of the Microbicide Trial Network (MTN) Combination 
HIV Antiretroviral Rectal Microbicide studies: A phase I 
clinical study evaluating different formulations of tenofovir 
1% gel as rectal microbicide 
  
May ’12 – Sept.’13 Co-investigator, Johns Hopkins University School of 
Medicine, Baltimore, MD 
Carried out a prospective cohort pharmacokinetic study to 
determine the adequacy of the revised WHO dosage 
recommendations for 1st line anti-TB medications in South 
African children. 
 
July ’02 – Sept ’02 Research Assistant, Bloomberg School of Public Health, 
Johns Hopkins University, Baltimore, MD 
Participated in NIH-funded clinical trial of Nevirapine for 
prevention of mother to child transmission of HIV in Addis 
Ababa, Ethiopia 
 
June ’00 – July ’01 Research Assistant, Walter Reed Army Institute of 
Research, Silver  
   Spring, MD 
Worked with a team focused on developing a vaccine 
















Hiruy H, Fuchs E, Marzinke M, Bakshi R et al. A Phase 1 Randomized, Blinded 
Comparison of the Pharmacokinetics and Colonic Distribution of Three 
Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated 
Unprotected sex (CHARM-02). AIDS Res Hum Retroviruses. 2015;31(11): 1098-
108 
 
McGowan I, Cranston R, Duffill K, Siegel A, Engstrom J, Nikiforov A, Jacobson 
C, Rehman K, Elliot J, Khanukhova E, Abebe K, Mauck C, Spiegel H, Dezzutti C, 
Rohan L, Marzinke M, Hiruy H, Hendrix C, Richardson-Harman N, Anton P. A 
Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, 
Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of 
Tenofovir 1% Gel (the CHARM-01 Study). PLoS One. 2015; 10(5):e0125363 
 
Hiruy H*, Rogers Z*, Mbowane C, et al. Subtherapeutic Concentrations of First-
line Anti-Tuberculosis Drugs in South African Children Treated According to the 
Current Guidelines: The PHATISA study. Journal of Antimicrobial Chemotherapy. 







Jain SK, Hiruy H. 2011. Extra-pulmonary tuberculosis. In: Clinical Decision Support in 
Infectious Diseases, Karchmer A, Southwick F, Wenzel R and Frank I (eds). Decision 
Support in Medicine, LLC.  
 
Hiruy H, Gowtham S, Sue . Recommended empiric antimicrobial therapy for 
selected clinical syndromes. In: The Harriet Lane Handbook of Pediatric 
Antimicrobial Therapy. 2nd ed. McMillan, J et al(eds), 2014 (Elsevier saunders, 
Philadelphia PA). 
 
Hiruy H, Agwu A. Human immunodeficiency virus infection. In:  Cabana MD, 
Brakeman P, Curran M, Dimeglio DA, Golden WC, Goldsby R, Hartman A, Kind 
T, Lightdale JL, Sabella C, Tanel R (editors). The 5-Minute Pediatric Consult, 7
th
 
edition.  Philadelphia, PA: Lippincott, Williams, and Wilkins,  in press. 
 
 





2012 Hiruy H, Mbowane C, Adamson J. et al. Anti-Tuberculosis Agents in 
Children. NIAID/IDSA ID Research Careers Meeting, 2012, Bethesda, 
Maryland 
 
2013 Hiruy  H, Mbowane C, Adamson J.  et al. Pharmacokinetics of Anti-
Tuberculosis Drugs in South African Children.7th International AIDS 
Society Conference on HIV Pathogenesis and Treatment and Prevention, 
Kuala Lampur, Malaysia 
            
 
Reviewer 
Journal of Acquired Immunodeficiency Syndrome-2012 
Pediatric Infectious Disease Journal-2011 
 
Leadership Experience 
July ’10 – July ‘15          Pediatric Diversity Council Board Member 
                                       Johns Hopkins University School of Medicine, Baltimore, MD 
August ’01 – May ’05     Student National Medical Association 
                                       Johns Hopkins University School of Medicine, Baltimore, MD 
 
August ’98 – May ’01    Ethiopian Student Association International 
                                       University of Maryland at College Park, MD 
 
 
Certification and Licensure 
American Board of Pediatric Infectious Disease     2013-present 
American Board of Pediatrics                                  2010-present 
Basic Life Support Certificate                                  2013-present 
Pediatric Advanced Life Support Certificate            2013-present 
 
Maryland State Medical license                               2013-present 
Washington State Medical license                           2010-present 
 
 
Academic Society Memberships 
American Academy of Pediatrics 
Infectious Disease Society of America 
Pediatric Infectious Disease Society 
National Institute of Health Women of Color Research Network 
Alpha Lambda Delta National Honor Society 






Proficient in English and Amharic (national language of Ethiopia) 
Basic skill in Swahili 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
